<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003462.pub3" GROUP_ID="VASC" ID="318100091108143910" MERGED_FROM="" MODIFIED="2014-06-24 12:54:14 +0100" MODIFIED_BY="Diane Horsley" REVIEW_NO="0007" REVMAN_SUB_VERSION="5.3.0 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2014-06-24 12:54:14 +0100" MODIFIED_BY="Diane Horsley">
<TITLE MODIFIED="2014-04-01 02:32:21 +0100" MODIFIED_BY="[Empty name]">Heparin versus placebo for non-ST elevation acute coronary syndromes</TITLE>
<CONTACT MODIFIED="2014-06-24 12:54:14 +0100" MODIFIED_BY="Diane Horsley"><PERSON ID="z1312061231141312115076313704410" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Andrade-Castellanos</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Specialist in Internal Medicine</POSITION><EMAIL_1>caandrade@hcg.gob.mx</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"</ORGANISATION><ADDRESS_1>Salvador Quevedo y Zubieta No. 750</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44340</ZIP><REGION>Jalisco</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 361 893 26</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-06-24 12:54:14 +0100" MODIFIED_BY="Diane Horsley"><PERSON ID="z1312061231141312115076313704410" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Andrade-Castellanos</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Specialist in Internal Medicine</POSITION><EMAIL_1>caandrade@hcg.gob.mx</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"</ORGANISATION><ADDRESS_1>Salvador Quevedo y Zubieta No. 750</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44340</ZIP><REGION>Jalisco</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 361 893 26</PHONE_1></ADDRESS></PERSON><PERSON ID="z1310101556018579415993652055074" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Luis</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Colunga-Lozano</LAST_NAME><POSITION>Medical Resident</POSITION><EMAIL_1>dr.colunga.lozano@gmail.com</EMAIL_1><EMAIL_2>fire_hawk2002@hotmail.com</EMAIL_2><MOBILE_PHONE>+52 (044) 33 15 18 66 39</MOBILE_PHONE><ADDRESS><DEPARTMENT>Servicio de Medicina Interna</DEPARTMENT><ORGANISATION>Hospital civil de Guadalajara Dr. Juan I Menchaca</ORGANISATION><ADDRESS_1>Salvador Quevedo y Zubieta n 750</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44320</ZIP><REGION>Guadalajara</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 36383409</PHONE_1></ADDRESS></PERSON><PERSON ID="z1310101602154827271983648865722" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Netzahualpilli</FIRST_NAME><LAST_NAME>Delgado-Figueroa</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>netscience89@gmail.com</EMAIL_1><URL>http://sociedadmbe.org</URL><MOBILE_PHONE>+52 33 11355619</MOBILE_PHONE><ADDRESS><DEPARTMENT>Primary Care Physician</DEPARTMENT><ORGANISATION>University of Guadalajara</ORGANISATION><ADDRESS_1>Ruiseñor 1369,  Fraccionamiento 8 de julio</ADDRESS_1><CITY>Guadalajara</CITY><ZIP>44910</ZIP><REGION>Jalisco</REGION><COUNTRY CODE="MX">Mexico</COUNTRY><PHONE_1>+52 33 38109134</PHONE_1></ADDRESS></PERSON><PERSON ID="13890" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kirk</FIRST_NAME><LAST_NAME>Magee</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>kmagee@dal.ca</EMAIL_1><EMAIL_2>kmagee@hfx.eastlink.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Dalhousie University</ORGANISATION><ADDRESS_1>Queen Elizabeth II Health Sciences Centre, Halifax Infirmary</ADDRESS_1><ADDRESS_2>1796 Summer Street</ADDRESS_2><CITY>Halifax</CITY><ZIP>B3H 3A7</ZIP><REGION>NS</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 902 473 8564</PHONE_1><PHONE_2>+1 902 431 0860</PHONE_2><FAX_1>+1 902 473 3617</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-02-08 18:09:11 +0000" MODIFIED_BY="Karen Hovhannisyan">
<UP_TO_DATE>
<DATE DAY="8" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-06-23 10:11:54 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-06-23 10:11:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Search updated to January 2014. Methodology of the review updated to incorporate 'Risk of bias' and 'Summary of findings´ tables.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-06-23 10:11:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="2" YEAR="2014"/>
<DESCRIPTION>
<P>Title of the review was changed to reflect the population evaluated. New authors have taken over this review. </P>
<P>The review was updated with nine additional excluded studies. No new studies were found for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-02-08 18:16:40 +0000" MODIFIED_BY="Joey Kwong">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2014-02-08 18:16:40 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>Feedback and author response added. Due to unforeseen circumstances, the feedback was not published when received in August 2008. The Cochrane Heart Group apologises for the delay</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-27 10:46:10 +0100" MODIFIED_BY="Joey Kwong">
<DATE DAY="8" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="28" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-01-31 18:43:06 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-01-31 18:43:06 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Department of Emergency Medicine, Dalhousie University, Halifax</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Thomas Chalmers Centre for Systematic Reviews, University of Ottowa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-01-31 18:43:06 +0000" MODIFIED_BY="[Empty name]">
<NAME>Department of Internal Medicine, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"</NAME>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<DESCRIPTION>
<P>(Internal support for the update)</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Canada Institute of Health Research (CIHR), Ottawa, Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-23 19:11:49 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-06-19 20:48:36 +0100" MODIFIED_BY="Heather Maxwell">
<TITLE MODIFIED="2014-06-19 20:48:36 +0100" MODIFIED_BY="Heather Maxwell">Heparins reduce the number of heart attacks but caused more minor bleeding after non-ST elevation acute coronary syndromes compared with placebo</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-19 20:33:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>Blood clots in the arteries leading to the heart can cause acute coronary syndromes: unstable angina (a feeling of tightness in the chest) or a type of heart attack (non-ST segment myocardial infarction - NSTEMI). Drugs that prevent clots from forming (such as aspirin) or thin the blood (such as heparin) can relieve the problem. Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are two types of heparin. This review of trials found that UFH and LMWH when given to patients with high-risk unstable angina or NSTEMI in the acute phase of treatment, in addition to standard therapy with aspirin, prevent more heart attacks than placebo but do not reduce mortality, the need for revascularization procedures or recurrent angina. Although there was limited reporting of side-effects, heparins caused more cases of minor bleeding.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-06-19 20:33:31 +0100" MODIFIED_BY="Heather Maxwell">
<ABS_BACKGROUND MODIFIED="2014-06-19 20:29:39 +0100" MODIFIED_BY="Heather Maxwell">
<P>Non-ST elevation acute coronary syndromes (NSTEACS) represent a spectrum of disease including unstable angina and non-ST segment myocardial infarction (NSTEMI). Despite treatment with aspirin, beta-blockers and nitroglycerin, unstable angina/NSTEMI is still associated with significant morbidity and mortality. Although evidence suggests that low molecular weight heparin (LMWH) is more efficacious compared to unfractionated heparin (UFH), there is limited data to support the role of heparins as a drug class in the treatment of NSTEACS. This is an update of a review last published in 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-06-19 20:29:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>To determine the effect of heparins (UFH and LMWH) compared with placebo for the treatment of patients with non-ST elevation acute coronary syndromes (unstable angina or NSTEMI).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-06-19 20:30:08 +0100" MODIFIED_BY="Heather Maxwell">
<P>For this update the Cochrane Heart Group Trials Search Co-ordinator searched the Cochrane Central Register of Controlled Trials on <I>The Cochrane Library </I>(2013, Issue 12), MEDLINE (OVID, 1946 to January week 1 2014), EMBASE (OVID, 1947 to 2014 week 02), CINAHL (1937 to 15 January 2014) and LILACS (1982 to 15 January 2014). We applied no language restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-06-19 20:30:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomized controlled trials of parenteral UFH or LMWH versus placebo in people with non-ST elevation acute coronary syndromes (unstable angina or NSTEMI).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-06-19 20:30:39 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently assessed quality of studies and independently extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-06-19 20:31:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>There were no new included studies for this update. Eight studies (3118 participants) were included in this review. We found no evidence for difference in overall mortality between the groups treated with heparin and placebo (risk ratio (RR) = 0.84, 95% confidence interval (CI) 0.36 to 1.98). Heparins compared with placebo, reduced the occurrence of myocardial infarction in patients with unstable angina and NSTEMI (RR = 0.40, 95% CI 0.25 to 0.63, number needed to benefit (NNTB) = 33). There was a trend towards more major bleeds in the heparin studies compared to control studies (RR = 2.05, 95% CI 0.91 to 4.60). From a limited data set, there appeared to be no difference between patients treated with heparins compared to control in the occurrence of thrombocytopenia (RR = 0.20, 95% CI 0.01 to 4.24). Assessment of overall risk of bias in these studies was limited as most of the studies did not give sufficient detail to allow assessment of potential risk of bias.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-19 20:33:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>Compared with placebo, patients treated with heparins had a similar risk of mortality, revascularization, recurrent angina, and thrombocytopenia. However, those treated with heparins had a decreased risk of myocardial infarction and a higher incidence of minor bleeding. Overall, the evidence assessed in this review was classified as low quality according to the GRADE approach. The results presented in this review must therefore be interpreted with caution.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-23 19:11:49 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-06-19 20:36:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>Acute coronary syndromes represent a spectrum of disease ranging from unstable angina to non-ST segment myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). The pathophysiology of non-ST segment elevation acute coronary syndromes (NSTEACS), i.e. unstable angina and NSTEMI, involves the rupture or erosion of an atherosclerotic coronary plaque (<LINK REF="REF-Falk-1995" TYPE="REFERENCE">Falk 1995</LINK>), activation of the coagulation cascade, and adhesion, activation and platelet aggregation. Inflammation plays a central role in the pathogenesis of atherosclerosis. Macrophage infiltration of plaque is key to this process (<LINK REF="REF-Libby-2002" TYPE="REFERENCE">Libby 2002</LINK>). Until recently, a significant proportion of patients admitted with unstable angina progressed to myocardial infarction or died in hospital (<LINK REF="REF-Cairns-1989" TYPE="REFERENCE">Cairns 1989</LINK>; <LINK REF="REF-Cohen-1998" TYPE="REFERENCE">Cohen 1998</LINK>).</P>
<P>NSTEMI may be differentiated from unstable angina by the presence of elevated cardiac enzymes indicating actual progression to myocardial necrosis and infarction. Initially, however, the two entities may present identically. Both unstable angina and NSTEMI are differentiated from STEMI in that they are not amenable to either immediate reperfusion therapy with systemic fibrinolytic therapy or immediate percutaneous coronary intervention (PCI). The TIMI III trial assessed the role of fibrinolysis in NSTEACS. This trial evaluated patients with unstable angina or NSTEMI and objective evidence of coronary artery disease. Patients were treated with intravenous heparin and then randomly assigned to placebo or infusion of alteplase. Alteplase administration was not associated with any improvement in primary end points (death or myocardial infarction) at six weeks or one year (<LINK REF="REF-Anderson-1995" TYPE="REFERENCE">Anderson 1995</LINK>; <LINK REF="REF-TIMI-IIIB-1994" TYPE="REFERENCE">TIMI IIIB 1994</LINK>). There was also a trend toward a higher incidence of severe hemorrhagic events in the alteplase group, with intracerebral hemorrhage occurring in four patients versus no controls. Early risk assessment using a risk stratification tool, such as the TIMI risk score is recommended to guide the timing of coronary angiography and possible PCI in patients with NSTEACS (<LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>).</P>
<P>Given the role of thrombin in the pathogenesis of acute coronary syndromes, heparin has the potential to decrease the occurrence of these undesirable outcomes. Unfractionated heparin (UFH) is a heterogenous mixture of polysaccharide chains whose mechanism of action is mediated through a unique pentasaccharide with a high affinity for antithrombin III. This bond produces a conformational change that increases the ability of antithrombin III to deactivate thrombin, factor Xa and factor IXa. Unfortunately, only one third of the UFH molecules have antithrombin III activity and UFH non-specific binding to protein and cells results in a less predictable dose-response curve (<LINK REF="REF-Hirsh-1998" TYPE="REFERENCE">Hirsh 1998</LINK>). Low molecular weight heparin (LMWH), which is derived from the depolymerization of standard UFH into lower molecular weight fragments, has a number of theoretical advantages including a more predictable dose-response curve, longer half-life and a lower incidence of heparin-induced thrombocytopenia which may be explained by reduced binding to platelets (<LINK REF="REF-Weitz-1997" TYPE="REFERENCE">Weitz 1997</LINK>). Evidence suggests that LMWH is more efficacious compared to UFH (<LINK REF="REF-Eikelboom-2000" TYPE="REFERENCE">Eikelboom 2000</LINK>; <LINK REF="REF-Magee-2003" TYPE="REFERENCE">Magee 2003</LINK>), but current guidelines recommend anticoagulation with any form of heparin (LWWH or UFH) for all patients presenting with unstable angina or NSTEMI in addition to antiplatelet therapy (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects of the intervention</HEADING>
<P>Hemorrhage is the chief complication that may result from heparin therapy. By inhibiting blood coagulation, the heparins, generally cause a balancing act between prevention of thrombus formation and inhibition of physiological coagulation. The incidence of bleeding under heparin therapy is hard to define, as it depends on numerous parameters including the indication, dosage, method, and duration of heparin application, the definition of bleeding, patient characteristics and determinants of bleeding such as surgery and co-medication. In clinical trials, up to 30% of patients with acute coronary syndromes or undergoing PCI experience bleeding complications (<LINK REF="REF-Manoukian-2007" TYPE="REFERENCE">Manoukian 2007</LINK>). Heparin-induced thrombocytopenia is a life-threatening disorder that follows exposure to UFH or (less commonly) LMWH. Patients classically present with a low platelet count (&lt;150,000 per cubic millimeter) or a relative decrease of 50% or more from baseline (<LINK REF="REF-Warkentin-2003" TYPE="REFERENCE">Warkentin 2003</LINK>). The incidence of heparin-induced thrombocytopenia is variable and is influenced by the heparin formulation and the clinical context in which heparin is administered.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Why it is important to do this review</HEADING>
<P>Systematic reviews have shown a reduction in the risk of death or myocardial infarction in patients with unstable angina and NSTEMI treated with aspirin plus heparin compared with those treated with aspirin alone (<LINK REF="REF-Eikelboom-2000" TYPE="REFERENCE">Eikelboom 2000</LINK>; <LINK REF="STD-Oler-1996" TYPE="STUDY">Oler 1996</LINK>). Eikelboom et al. assessed the short-term and long-term effects of UFH and LMWH in patients with acute coronary syndromes without ST elevations. The comparisons included UFH and LMWH with placebo or untreated control, and UFH versus LMWH. Overall, short-term UFH or LMWH reduced the incidence of non-fatal myocardial infarction and death by 50%. However, there are some important limitations in these reviews. Firstly, the comprehensiveness of systematic literature searches is far from optimal. For instance, the literature search by Oler et al. was restricted exclusively to MEDLINE (<LINK REF="STD-Oler-1996" TYPE="STUDY">Oler 1996</LINK>); therefore, it is possible that relevant studies may have been overlooked. Secondly, assessments of risk of bias of studies are not specified in both reviews (<LINK REF="REF-Eikelboom-2000" TYPE="REFERENCE">Eikelboom 2000</LINK>; <LINK REF="STD-Oler-1996" TYPE="STUDY">Oler 1996</LINK>). Assessing the risk of bias of a study can be thought of as assessing the risk that the study results reflect bias in study design or execution rather than the true effect of the intervention or exposure under study. Risk of bias is interchangeable with internal validity and may overlap to a great extent with quality. Given the limitations of previous systematic reviews, we used specific methodology and criteria outlined by The Cochrane Collaboration to present a comprehensive systematic review of heparins (UFH and LMWH) in the acute treatment of NSTEACS.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-01 17:42:41 +0100" MODIFIED_BY="[Empty name]">
<P>To update the previously published review that examined the effects of heparin compared with placebo for the treatment of patients with non-ST elevation acute coronary syndromes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-19 20:42:01 +0100" MODIFIED_BY="Heather Maxwell">
<SELECTION_CRITERIA MODIFIED="2014-06-19 20:38:52 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES>
<P>To be considered, clinical studies were required to be randomized controlled trials, including multi-arm trials. Blinding was not a requirement.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-06-19 20:37:36 +0100" MODIFIED_BY="Heather Maxwell">
<P>Only studies that included adult patients (&gt; 18 years of age) presenting with non-ST elevation acute coronary syndromes requiring treatment within 72 hours of presentation of their last episode of chest pain were considered eligible for inclusion. Non-ST elevation acute coronary syndromes included unstable angina and NSTEMI. Unstable angina had to be characterized as typical chest pain lasting at least 10 minutes within 72 hours of presentation with either historic, electrocardiographic or angiographic evidence of underlying ischemic heart disease. NSTEMI had to be characterized as chest pain with ST segment depression and elevation of relative cardiac enzymes (total creatine kinase (CK) greater than twice the usual upper limit or CK-MB greater than the upper normal limit). Those studies where the patients were inpatients, had stable angina, were volunteers, or presented to non-Emergency Department settings were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-06-19 20:38:06 +0100" MODIFIED_BY="Heather Maxwell">
<P>All patients were required to receive aspirin therapy and be randomized to receive treatment with either parenteral unfractionated heparin (UFH) or low molecular weight heparin (LMWH) compared with placebo or untreated control within 72 hours of presentation. Because platelets play an important role in the development of thrombosis, antiplatelet agents are a mainstay of the treatment of non-ST elevation acute coronary syndromes. Aspirin is recommended by guidelines as acute and long-term treatment for all patients with non-ST elevation acute coronary syndromes unless it is contraindicated (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). By the time of the original review, aspirin was the standard of care for patients with unstable angina and NSTEMI.</P>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<UL>
<LI>Parenteral UFH or LMWH.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparator</HEADING>
<UL>
<LI>Placebo or untreated control.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-19 20:38:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>Only studies reporting clinically relevant outcomes were considered. Outcomes over all time periods were considered. Outcomes included the following.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>Death (all-cause mortality).</LI>
<LI>Myocardial infarction.</LI>
<LI>Major hemorrhage (e.g. fall in hemoglobin level of &gt;2 g/dL, requires transfusion, is intracranial, retroperitoneal, or intraocular, or causes death or cessation of the study treatment).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Recurrent angina (e.g. anginal chest pain that requires nitroglycerin infusion to be restarted).</LI>
<LI>Revascularization procedures (e.g. angioplasty with or without stenting, coronary artery bypass grafting).</LI>
<LI>Minor hemorrhage (e.g. any clinically important bleed that does not qualify as major; e.g. epistaxis, ecchymosis or hematoma, or macroscopic hematuria).</LI>
<LI>Adverse events other than hemorrhage (thrombocytopenia).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-19 20:39:00 +0100" MODIFIED_BY="Heather Maxwell">
<P>We updated the previously-run searches from 2002 and searched the following databases up to 15 January 2014:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) on <I>The Cochrane Library </I>(2013, Issue 12);</LI>
<LI>MEDLINE (OVID, 1946 to January week 1 2014);</LI>
<LI>EMBASE Classic + EMBASE (OVID, 1974 to 2014 week 2);</LI>
<LI>CINAHL (EBSCO, 1937 to 15 January 2014);</LI>
<LI>LILACS (Bireme, 1982 to 15 January 2014).</LI>
</UL>
<P>The search strategies are listed in the <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. For this update, the randomized controlled trial (RCT) filter for MEDLINE is the Cochrane sensitivity and precision maximizing RCT filter, and for EMBASE, terms as recommended in <I>the</I> <I>Cochrane Handbook for Systematic Reviews of Interventions</I> have been applied. (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The RCT filter for CINAHL is based on SIGN and Cochrane filter terms (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-19 20:42:01 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors (KM and BR) scanned the titles and abstracts of each record retrieved from the searches for the original review. A new review author (CAC) did this for the update. If information in the title and abstract clearly indicated that the trial did not meet the inclusion criteria, we rejected the trial. When a title or abstract could not be rejected with certainty, we obtained the full-text article, and two review authors (KM and BR for original review; CAC and LCL for the update) independently inspected it. We resolved any uncertainties or disagreements on whether papers were eligible for inclusion by consensus in the presence of a third investigator. If we excluded a trial, we recorded both the article citation and the reason for exclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management</HEADING>
<P>For the original review, two review authors (BR, KM) independently extracted data using a standardized form (data extraction sheet based on the Cochrane Consumers and Communication Review Group&#8217;s data extraction template). Discrepancies were resolved through consensus or in consultation with a third author.</P>
<P>Data extraction included the following items.</P>
<UL>
<LI>Population: age, gender, time to presentation, inclusion and exclusion criteria</LI>
<LI>Type of intervention and control: agent, dose, duration of therapy, weight-based versus fixed dosing, target activated partial thromboplastin time (aPTT), time to adequate aPTT, and control used</LI>
<LI>Outcome: timing of primary outcome, assessors, adjudication, definition of: myocardial infarction, unstable angina, mortality</LI>
<LI>Side-effect profile: designation of minor and major bleeding</LI>
<LI>Design: parallel group versus cross-over; method of randomization, blinding and follow-up</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>Two review authors (CAC and NDF for the update) independently assessed risk of bias in the included studies using The Cochrane Collaboration &#8216;Risk of bias&#8217; tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), as described in Chapter 8 of <I>the</I> <I>Cochrane Handbook for Systematic Reviews of Interventions. </I>Any disagreements concerning risk of bias were resolved by discussion. We displayed the results by creating a &#8217;Risk of bias&#8217; summary (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and a &#8217;Risk of bias&#8217; graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) using RevMan 5.2 software. For each domain of risk of bias, we described what was reported to have happened in the study in order to provide a rationale for the second part, which involved assigning a judgement of 'Low risk&#8217; of bias, 'High risk&#8217; of bias, or 'Unclear risk&#8217; of bias. For each included study, we assessed the following seven domains of risk of bias.</P>
<UL>
<LI>Random sequence generation (selection bias)</LI>
<LI>Allocation concealment (selection bias)</LI>
<LI>Blinding of participants and personnel (performance bias)</LI>
<LI>Blinding of outcome assessment (detection bias)</LI>
<LI>Incomplete outcome data (attrition bias)</LI>
<LI>Selecting reporting (reporting bias)</LI>
<LI>Other bias</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>Measures of treatment effect</I>
</HEADING>
<P>All trials were combined using Review Manager, version 5.2 (Nordic Cochrane Centre, Copenhagen, Denmark). For dichotomous variables, individual and pooled statistics were calculated as risk ratios (RR) with 95% confidence intervals (95% CI). DerSimonian&#8211;Laird random-effects models (<LINK REF="REF-DerSimonian-1987" TYPE="REFERENCE">DerSimonian 1987</LINK>) were used when more than five trials were pooled. When fewer trials or no heterogeneity was identified, a fixed-effect model was employed. If identified, for continuous outcomes, we planned to calculate individual and pooled statistics as mean differences (MD) or standardized mean differences (SMD) and 95% CIs using a random-effects model. The presence of publication bias was examined visually using a funnel plot.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assesment of heterogeneity</HEADING>
<P>The impact of statistical heterogeneity was quantified using the I<SUP>2</SUP> statistic. The thresholds of I<SUP>2</SUP> recommended by <I>the Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) are:<BR/>&#8226; 0% to 40%: might not be important;<BR/>&#8226; 30% to 60%: may represent moderate heterogeneity;<BR/>&#8226; 50% to 90%: may represent substantial heterogeneity;<BR/>&#8226; 75% to 100%: considerable heterogeneity.</P>
<P>We used subgroup analyses planned a priori<I> </I>to investigate possible differences between the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>Two specific subgroups were planned a priori:</P>
<P>a) Population: unstable angina versus unstable angina and NSTEMI; and<BR/>b) Intervention: UFH versus LMWH.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>Possible sources of heterogeneity were assessed by sensitivity analysis that included only trials of good quality. We defined a good-quality study as one which fulfils all of the following criteria: adequate allocation concealment, blinding of outcome assessment and data analysis performed according to the intention-to-treat principle.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>For this update, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for evaluating quality of the evidence of systematic reviews (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) was adopted using the software GRADEprofiler. The quality of the body of evidence was assessed with reference to the overall risk of bias of the included studies, the directness of the evidence, the inconsistency of the results, the precision of the estimates, and the risk of publication bias. The quality of the body of evidence was classified into four categories: high, moderate, low and very low.<BR/>
</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-06-23 19:11:49 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-06-23 17:39:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Results of the search</HEADING>
<P>The computerized search of EMBASE, MEDLINE and CINAHL of the original review (2002) identified 2193 original publication citations. Independent review of the abstracts and titles of these publications identified 56 potentially relevant studies. Of these potentially relevant articles, eight studies met the inclusion criteria, with a total of 3118 patients being included in this systematic review. One potentially relevant abstract is awaiting assessment as detailed methodology and outcomes have not been possible to obtain (<LINK REF="STD-Zwerner-1987" TYPE="STUDY">Zwerner 1987</LINK>).</P>
<P>The 2014 update of the search resulted in 2681 extra citations. One review author (CAC) examined the titles and abstracts and retrieved full-text articles where necessary. This resulted in the addition of nine new references to nine studies (<LINK REF="STD-Brown-1964" TYPE="STUDY">Brown 1964</LINK>; <LINK REF="STD-Cohen-2003" TYPE="STUDY">Cohen 2003</LINK>; <LINK REF="STD-COMPARE-2010" TYPE="STUDY">COMPARE 2010</LINK>; <LINK REF="STD-CREATE-2005" TYPE="STUDY">CREATE 2005</LINK>; <LINK REF="STD-Massel-2002" TYPE="STUDY">Massel 2002</LINK>; <LINK REF="STD-OASIS_x002d_6-2006" TYPE="STUDY">OASIS-6 2006</LINK>; <LINK REF="STD-Oldgren-2008" TYPE="STUDY">Oldgren 2008</LINK>; <LINK REF="STD-Peterson-2001" TYPE="STUDY">Peterson 2001</LINK>; <LINK REF="STD-Tanajura-1993" TYPE="STUDY">Tanajura 1993</LINK>). Three additional myocardial infarction studies were considered for inclusion but all study participants had confirmed ST-segment elevation myocardial infarction (STEMI) (<LINK REF="STD-Brown-1964" TYPE="STUDY">Brown 1964</LINK>; <LINK REF="STD-CREATE-2005" TYPE="STUDY">CREATE 2005</LINK>; <LINK REF="STD-OASIS_x002d_6-2006" TYPE="STUDY">OASIS-6 2006</LINK>).These studies therefore needed to be excluded. The main reasons for exclusion of the rest of the studies that appeared eligible for this review were (a) not a randomized controlled trial, and (b) heparin not compared versus placebo. The full list of excluded studies and reasons for exclusion are given in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>There were no new included studies for this update. Eight studies with a total of 3118 patients treated with either UFH or LMWH were included. In total, 1602 patients (52%) were eligible to receive LMWH and 1508 patients (48%) were eligible to receive UFH. The average age at randomization was 62 years. The majority of trials enrolled male patients (75%) with unstable angina (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>).</P>
<P>Two different LMWHs were used: dalteparin (1498 eligible patients) and nadroparin (104 eligible patients). Of the patients receiving UFH, 19% were switched to warfarin when the UFH was discontinued. Most trials mandated that participants received study medication within 24 hours of the most recent episode of chest pain; however, some patients received it as late as 48 hours in two studies (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>) and up to 72 hours in two other studies (<LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>). The duration of treatment varied among the different studies with a range of two to seven days. Aspirin (75 to 325 mg per day) was a standard concomitant intervention in all of the studies. Treatment with other anti-anginal medications (e.g. nitroglycerin, beta-blockers and calcium channel blockers) was at the discretion of the attending physician in most studies. Patients were selected on the basis of narrow inclusion criteria. They had to have a history of unstable angina plus one of the following: a previous history of known coronary artery disease (defined as a prior myocardial infarction, positive exercise stress test or angiographic evidence), ECG changes, or cardiac enzyme elevation. One study (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>) stipulated that patients had to present with angina within two weeks to six months following coronary angioplasty.</P>
<P>All studies were RCTs; however, not all were double blind. Three studies (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>) reported on outcomes only over the duration of the hospital admission. In one study (<LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>), only data from the in-patient arm of the study was used although patients were followed up for five to seven months. In all other studies, however, the patients were followed up and the outcomes measured at three months. A variety of outcome measures were reported. Death, myocardial infarction, recurrent angina, revascularization and major bleeds were the most commonly reported outcomes across the studies. One study (<LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>) reported a combined end point of death or myocardial infarction and it was not possible to separate the individual event rates. Death was reported as 'all-cause' and secondary to myocardial infarction in most studies. Myocardial infarction was clearly defined as typical chest pain associated with the appearance of new significant ECG changes (new ST-T changes, loss of R-wave amplitude or development of Q-waves), and the subsequent elevation of serum cardiac enzymes (creatine kinase, plus or minus MB fraction) beyond levels drawn at enrollment. The definition of recurrent angina varied among the studies. Of the six papers which included recurrent angina as a study end point, three required a history of typical chest pain accompanied by ECG changes (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). The other three studies either did not require associated ST segment changes to diagnose recurrent angina or were unclear how they defined this end point (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>). The indications for revascularization were not well defined in most studies with 'severe refractory/recurrent ischemia' being the most common criteria. The definition of major bleeding complications was consistent across all studies. Minor bleeds and the incidence of thrombocytopenia were only reported in three and two studies respectively.</P>
<P>The timing of the end points was inconsistent among the trials ranging from 48 hours to three months. In four studies, endpoints were recorded over a five- to eight-day period (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>), while in the other four studies, end points were measured at three months (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). We have grouped the results for all reported time periods.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-06-19 20:45:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>For this update, two authors (CAC and NDF) independently assessed risk of bias of the trials. For this purpose, instructions given in <I>the Cochrane Handbook for Systematic Reviews </I>of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) were followed.</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation</HEADING>
<P>The sequence generation for participant allocation was adequate in only two studies (<LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). Both studies used blocked randomization to determine the allocation for the two comparison groups. In six studies, the method of sequence generation was unclear or not specified (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>). In relation to concealment of the allocation sequence, in two of the studies the pharmacy assigned eligible participants randomly (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>;). The rest of the studies provided insufficient information about concealment of the allocation sequence (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Three trials adequately reported blinding of participants (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>), while only one study adequately reported blinding of assessors and personnel (<LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). Two trials did not blind participants, personnel, or outcome assessors (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>).Two trials did not blind participants and was unclear about the blinding of assessors (<LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>). Blinding of outcome assessors was unclear in five trials (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incomplete outcome data</HEADING>
<P>The number of missing data was equally distributed between treatment and control group in six trials (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). Two studies reported to have complete data for all included participants (<LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selective reporting</HEADING>
<P>No study protocol was available for the evaluated studies (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>), but all clinically expected outcomes were reported. Publication bias for the incidence of multiple end points (death or myocardial infarction) over all time periods was examined visually in the form of funnel plot. The funnel plot indicates that there may be publication bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). However, the number of studies is considered insufficient to meet rigorous criteria for creating a funnel plot (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other potential sources of bias</HEADING>
<P>Two studies (<LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>) were stopped early. One of these trials was stopped early due to benefit with nadroparin and more bleeding with heparin (<LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>).The other study was discontinued prematurely on the basis of the policy board (<LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-06-23 19:11:49 +0100" MODIFIED_BY="[Empty name]">
<P>As the timing of outcomes varied between studies, the results are tabulated over all time periods.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<P>
<B>Death</B>
</P>
<P>Death was reported as an outcome in six trials involving 2426 patients (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). The incidence of death in those treated with placebo was 0.9% (11/1188) compared to 0.7% (9/1238) in those treated with an heparin. Overall, there was a trend towards fewer deaths in the heparin group compared to the placebo group; however, this was not statistically significant (risk ratio (RR) = 0.84, 95% confidence interval (CI) 0.36 to 1.98, P = 0.82, I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>
<B>Myocardial infarction</B>
</P>
<P>Myocardial infarction was reported as an outcome in six trials involving 2426 patients (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). Heparins were superior to placebo in preventing myocardial infarction (RR = 0.40, 95% CI 0.25 to 0.63, P = 0.63, I<SUP>2</SUP> = 0.0%). The overall incidence of myocardial infarction was 4.8% (57/1188) in those treated with placebo compared to 1.9% (24/1238) in those treated with heparin. Given the risk difference of -0.03 (95% CI -0.01 to -0.04), 33 (95% CI 25 to 100) patients would need to be treated with either type of heparin to prevent one additional myocardial infarction in patients presenting with acute coronary syndromes (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>
<B>Major bleeds</B>
</P>
<P>All eight trials, involving 3118 patients, reported major bleeds as an outcome (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). Major bleeding was defined as a fall in hemoglobin of more than 2 g/dL, or bleeding leading to transfusion in seven trials (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). The RISC trial reported no major bleeds (<LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>). There was a trend towards more major bleeds in the heparin studies compared to control studies (RR = 2.05, 95% CI 0.91 to 4.60, I<SUP>2</SUP> = 0.0%). In the two studies that treated patients with warfarin after initial heparin (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>), there was a trend towards more major bleeds (RR = 7.26, 95% CI 0.38 to 138). No heterogeneity was observed in this outcome (P = 0.93) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>
<B>Recurrent angina</B>
</P>
<P>Recurrent angina was reported as an outcome in six studies involving 2426 patients (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). There was evidence of heterogeneity in this data set (P &lt; 0.01) and a random-effects model was used to calculate the pooled statistic. Although heparins as a group showed a trend towards preventing recurrent angina compared to placebo, this result was not statistically significant (RR = 0.81, 95% CI 0.60 to 1.09; I<SUP>2</SUP> = 65.0%) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>
<B>Revascularization procedures</B>
</P>
<P>The need for a revascularization procedure was reported as an outcome in six of the eight included studies involving 2520 patients (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). The pooled results from these studies failed to demonstrate a benefit of heparins compared to aspirin plus placebo in preventing revascularization procedures (RR = 0.93, 95% CI 0.76 to 1.15, I<SUP>2</SUP> = 41.1%) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>
<B>Multiple end points</B>
</P>
<P>We were able to calculate the incidence of death or<B> </B>myocardial infarction for all eight included studies (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). Patients who were treated with heparins were less likely to experience one of these outcomes compared to those treated with placebo (RR = 0.61, 95% CI 0.47 to 0.80, I<SUP>2</SUP> = 26.5%). No significant heterogeneity was identified in this result (P = 0.22). The incidence of death or myocardial infarction was 4.9% (79/1602) for patients treated with heparins compared to 7.6% (115/1508) for those treated with placebo. Given a risk difference of -0.03 (95% CI -0.01 to -0.05), 33 (95% CI 20 to 100) patients would need to be treated with heparin to prevent one additional death or myocardial infarction (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>
<B>Minor bleeds</B>
</P>
<P>Only three of the eight included studies (n = 1931) reported minor bleeds as an outcome (<LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>). Data from the analysis indicated heterogeneity (P &lt; 0.03) so a random-effects model was used to pool data. Patients who were treated with heparins experienced significantly more minor bleeds compared to patients treated with placebo (RR = 6.80, 95% CI 1.23 to 37.49, I<SUP>2</SUP> = 66.9%). In the heparin group, 8.0% (79/989) of patients experienced minor bleeding compared to only 0.5% (5/942) in control group. This represents a risk difference of 0.06 (95% CI 0.02 to 0.11), such that for every 17 (95% CI 9 to 50) patients treated with heparin, one additional case of minor bleeding was observed (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
<P>
<B>Thrombocytopenia</B>
</P>
<P>Only two studies (n = 1717) reported the outcome of thrombocytopenia (<LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>). From this limited data set, there appeared to be no difference between patients treated with heparins compared to control in the occurrence of thrombocytopenia (RR = 0.20, 95% CI 0.01 to 4.24, I<SUP>2</SUP> = 0.0%) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>Sensitivity analysis based on random-effects versus fixed-effect modeling yielded very similar overall results. With the exception of recurrent angina, the pooled statistic for all other outcomes was essentially unchanged regardless of whether a random-effects or fixed-effect model was chosen. If a fixed-effect instead of a random-effects model had been used for recurrent angina, the point estimate would have essentially remained unchanged; however, the narrowed 95% CIs would result in a statistically significant reduction of recurrent angina with heparins compared to aspirin alone (RR = 0.79, 95% CI 0.67 to 0.93). The trial quality assessment eliminated four papers, approximately 25% of enrolled participants. When this sensitivity analysis (e.g. excluding these studies) was performed, there were no important changes in these pooled results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>Subgroup analysis based on whether patients had unstable angina versus a NSTEMI was not possible in this review, since subgroup data could not be obtained from the studies.</P>
<P>Subgroup comparisons based on whether UFH or LMWH was used were difficult to make due to small study numbers. Of the eight included studies, only two (<LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>) compared LMWH versus placebo. It is interesting to note, however, that only the LMWH subgroup showed a statistically significant benefit over the control group in any of the outcomes studies. Higgins and Thompson (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>) propose the I<SUP>2</SUP> statistic which describes the percentage of total variation across<B> </B>studies due<B> </B>to heterogeneity rather than chance. Using their methods, significant and important heterogeneity was identified with respect to the incidence of recurrent angina (P = 0.01 and I<SUP>2</SUP> = 65%) and revascularization procedures (P = 0.12 and I<SUP>2</SUP> = 41%). When the data were analyzed according to the treatment received, clinically important subgroups were identified. The pooled analysis from the LMWH subgroup showed statistically significant benefit with respect to the incidence of recurrent angina (P = 0.52; 95% CI 0.36 to 0.74) and revascularization procedures (P = 0.26; 95% CI: 0.09 to 0.78), even though this benefit was lost when all heparins were grouped together.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-06-23 17:42:57 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review examined the best available evidence for the use of heparins in the treatment of non-ST elevation acute coronary syndromes and identified several important outcomes related to their use. Overall, heparins as a group failed to demonstrate a statistically significant reduction in mortality, although a beneficial effect as great as a 64% reduction or an increased risk of 98% can not be excluded. Given the low incidence of death in the included studies (~1% to 2%), this systematic review is under-powered to detect small treatment differences. For this outcome, the systematic review had 80% power to detect a relative reduction in risk of 84% (from 0.93% to 0.15%). Approximately 4900 patients in each group would have been required to detect a 50% relative reduction in risk (power = 80%, two-sided alpha = 0.05). Treatment with heparins did, however, reduce the incidence of myocardial infarction such that 33 patients needed to be treated with heparin to prevent one additional myocardial infarction. For most of the other outcomes, the benefit of using heparins was less clear.</P>
<P>Half of all participants randomized to receive heparin in this review were eligible to receive LMWH. When these studies were pooled, LMWH proved to be superior to placebo, not only with reducing the incidence of myocardial infarction, but also with reducing the incidence of recurrent angina and the need for revascularization procedures. Again, although statistically significant, the absolute risk reductions were small (1% to 3%), suggesting caution in the clinical interpretation of these findings.</P>
<P>Overall, little heterogeneity was identified in the pooled results reported in this review. This is not surprising given that non-ST elevation acute coronary syndromes represent a well-defined disease spectrum with fairly clear-cut dichotomous outcomes. Outcomes in which heterogeneity was identified included the incidence of recurrent angina and minor bleeds (I<SUP>2</SUP> = 65% and 67%, respectively). A moderate degree of heterogeneity was identified (I<SUP>2</SUP> = 41%) in the incidence of revascularization procedures. This can in part be accounted for by subtle differences in study design: inclusion criteria, dosing regimen, UFH versus LMWH use and timing of outcomes. To a larger extent, however, this heterogeneity may reflect the particular outcomes in question, the definitions of which varied between studies and local practices relating to revascularization procedures.</P>
<P>Overall, heparins appeared to be a safe treatment for non-ST elevation acute coronary syndromes. Although there was a trend towards more major bleeds in the heparin-treated group, this was not statistically significant. Not surprisingly, patients treated with heparins had a higher incidence of minor bleeding. It is difficult to comment on the rate of thrombocytopenia as only two studies commented on this rare, but potentially life-threatening complication of heparinization. This data must be interpreted with caution, however, as side-effects were poorly reported in most studies.</P>
<P>There is a possibility of publication bias in this systematic review. For example, by missing unpublished 'statistically' negative trials we may be over-estimating the effect of heparin treatment. However, a comprehensive search of the published literature for potentially relevant studies was conducted, using a systematic strategy to avoid bias. This was followed by attempts to contact corresponding and first authors. Although no unpublished or negative trials were identified, we recognize that these types of trials may exist. The funnel plot demonstrates asymmetry in the area of small negative trials, so this is a legitimate concern. Given the nature of the research (e.g. expensive, complex, difficult to fund), however, these small negative trials are unlikely, and would not be expected to influence the results. There is also a possibility of study selection bias. Four trials in which the study group did not receive aspirin or were compared versus a non-aspirin control were excluded (<LINK REF="STD-Averkov-1993" TYPE="STUDY">Averkov 1993</LINK>; <LINK REF="STD-Charvat-1989" TYPE="STUDY">Charvat 1989</LINK>; <LINK REF="STD-Serneri-1995" TYPE="STUDY">Serneri 1995</LINK>; <LINK REF="STD-Th_x00e9_roux-1993" TYPE="STUDY">Théroux 1993</LINK>) because of the well-accepted treatment of acute coronary syndromes with aspirin (<LINK REF="REF-Lewis-1983" TYPE="REFERENCE">Lewis 1983</LINK>; <LINK REF="STD-Oler-1996" TYPE="STUDY">Oler 1996</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). However, we used two independent review authors, and feel confident that the studies excluded were done so for consistent and appropriate reasons. Our search was comprehensive and has been updated, so it is unlikely that we missed any published trials. Most studies restricted enrollment to patients who had either a documented history of coronary artery disease, ECG changes or cardiac enzyme elevation, which is somewhat different from the patient population traditionally treated with heparins for acute coronary syndrome (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>).</P>
<P>In recent years, the administration of clopidogrel in addition to aspirin and heparin has been shown to be of benefit as initial medical treatment of patients with unstable angina and NSTEMI. Following the results of the CURE trial (<LINK REF="REF-Yusuf-2001" TYPE="REFERENCE">Yusuf 2001</LINK>), dual antiplatelet treatment with clopidogrel combined with aspirin became the standard of care in patients with NSTEACS (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>; <LINK REF="REF-ESC-Guidelines-NSTEACS-2011" TYPE="REFERENCE">ESC Guidelines NSTEACS 2011</LINK>). The evidence evaluated in this review comes from older trials where the use of P2Y12 receptor blockers were not in wide use. Thus, the results of our meta-analysis may not be totally applicable to patients with NSTEACS treated with dual antiplatelet therapy. Recent systematic reviews and meta-analyses of randomized controlled trials have shown that dual therapy with aspirin and clopidogrel is beneficial in patients with acute coronary syndromes with a favorable benefit-risk profile (<LINK REF="REF-Bowry-2008" TYPE="REFERENCE">Bowry 2008</LINK>; <LINK REF="REF-Eshaghian-2007" TYPE="REFERENCE">Eshaghian 2007</LINK>; <LINK REF="REF-Zhou-2012" TYPE="REFERENCE">Zhou 2012</LINK>). However, as antiplatelet therapy becomes more potent, bleeding risk has become a concern (<LINK REF="REF-Zhou-2012" TYPE="REFERENCE">Zhou 2012</LINK>).</P>
<P>This systematic review illustrates the potential benefit of using heparins in the early treatment of non-ST elevation acute coronary syndromes. These results are concordant with the most current recommendations made by the American Heart Association (<LINK REF="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" TYPE="REFERENCE">ACCF/AHA Guideline NSTEACS 2013</LINK>) and similar to two previous reviews (<LINK REF="REF-Eikelboom-2000" TYPE="REFERENCE">Eikelboom 2000</LINK>; <LINK REF="STD-Oler-1996" TYPE="STUDY">Oler 1996</LINK>).The AHA suggests using either LMWH or UFH in patients with unstable angina/NSTEMI in addition to antiplatelet therapy as soon as possible after presentation.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of evidence</HEADING>
<P>A total of eight studies were included in this review with a total of 3118 patients. According to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the quality of the evidence was low for all clinically important outcomes. All the included studies were prospective, randomized controlled trials but only one of the included studies was assessed at low risk of bias (<LINK REF="STD-Th_x00e9_roux-1988" TYPE="STUDY">Théroux 1988</LINK>). For all domains, five studies (62%) were at unclear risk of bias for at least one domain (<LINK REF="STD-Doucet-2000" TYPE="STUDY">Doucet 2000</LINK>; <LINK REF="STD-FRISC-1996" TYPE="STUDY">FRISC 1996</LINK>; <LINK REF="STD-Holdright-1994" TYPE="STUDY">Holdright 1994</LINK>; <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>; <LINK REF="STD-RISC-1990" TYPE="STUDY">RISC 1990</LINK>). Three of the included studies were at high risk of bias in two domains (<LINK REF="STD-Cohen-1990" TYPE="STUDY">Cohen 1990</LINK>; <LINK REF="STD-Cohen-1994" TYPE="STUDY">Cohen 1994</LINK>, <LINK REF="STD-Gurfinkel-1995" TYPE="STUDY">Gurfinkel 1995</LINK>) see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>Regarding the quality of evidence, we conclude that there is insufficient evidence to draw meaningful conclusions about the benefits and harms of heparins in non-ST elevation acute coronary syndromes. Overall, the methodological quality of trials was far from optimal.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-19 20:47:47 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-19 20:47:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>This systematic review of randomized controlled trials supports the use of heparins in the early treatment of non-ST elevation acute coronary syndromes. Given in addition to aspirin to patients with a history of typical angina accompanied by either a past medical history of coronary artery disease or ECG/cardiac enzyme changes, heparins reduced the incidence of myocardial infarction, but not mortality. In this review, heparins were given within 24 to 72 hours of the onset of symptoms as a weight-adjusted dose for a five to eight day period, with most studies administering it for two to seven days. The small number of studies makes it impossible to recommend a particular dosing regimen. Indirect comparisons of the pooled results of trials of UFH versus placebo with the pooled results of trials of LMWH versus placebo may be interpreted as suggesting that LMWH is more effective than UFH as a subgroup. However, indirect comparisons are unreliable and potentially misleading because of differences in the kinds of patients randomized, outcome definitions, and treatment regimens.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-06-19 20:47:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>Despite the strength of the findings of this review, there are several areas in which questions remain unanswered.<BR/>
</P>
<UL>
<LI>Currently, the optimal time of treatment initiation is unclear. The eight studies examined three different time periods: within 24, 48 and 72 hours. It would be interesting to determine whether the timing of heparin administration (in the emergency department versus on the ward) affects outcomes.</LI>
<LI>Given the interventional nature of the investigation and treatment of acute coronary syndromes, the optimal duration of heparin treatment remains controversial. Whether shorter duration treatments might be as effective remains an interesting, yet unresolved, question.</LI>
<LI>Patient-centered outcomes such as quality of life have not been studied and are particularly warranted. In addition, considering the cost of these drugs, prospective cost-effectiveness analyses will be desirable.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-02-03 02:53:28 +0000" MODIFIED_BY="[Empty name]">
<P>For this update, the authors would like to thank the Cochrane Heart Group editorial base for their support. We also acknowledge the contribution of the previous authors who were no longer able to approve update review: Moher D, Rowe BH and Campbell S.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-02-03 19:01:31 +0000" MODIFIED_BY="[Empty name]">
<P>The authors who have been involved in this review have done so without any known conflicts of interest. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-06-19 20:47:55 +0100" MODIFIED_BY="Heather Maxwell">
<P>Andrade-Castellanos CA: Editing manuscript, study selection, quality and 'Risk of bias' assessment, data entry and analysis, report writing and editing entry and analysis, report writing and editing, Current primary author.</P>
<P>Colunga-Lozano L: Editing manuscript, study selection, data entry and analysis.</P>
<P>Delgado-Figueroa N: Editing manuscript, quality and 'Risk of bias' assessment.</P>
<P>Magee KD: Protocol development, grant writing, study selection and quality assessment, data entry and analysis, report writing and editing entry and analysis, report writing and editing.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-06-19 20:48:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>As acknowledged, in 2014 our group was granted to continue and prepare the review. The published protocol originally prepared by Magge et al dates back to 2002. During the update process, the title of the review changed from <I>Heparin versus placebo for acute coronary syndromes (ACS)</I> to <I>Heparin versus placebo in non-ST elevation acute coronary syndromes (NSTEACS)</I> in order to reflect the population evaluated.</P>
<P>In the words of Kirk Magee, STEMI patients were excluded from this review because it was felt that patients with STEMI categorically differed from patients with unstable angina/NSTEMI with respect to their presentation, underlying pathophysiology and treatment. Clinically, patients with STEMI are different than patients with unstable angina/NSTEMI Including patients with STEMI would introduce significant heterogeneity in the results and would not allow for the performance of a meta-analysis. Also, when the review was first published, the term ACS was inclusive of unstable angina/NSTEMI and did not include STEMI.</P>
<P>We take the rationale of Kirk Magee as our own. However, in order to avoid misleading conclusions regarding the diversity of patients with ACS, we, in agreement with Kirk Magee, decided to change the title of this Cochrane review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-06-24 12:26:56 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-06-24 12:26:56 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-06-18 15:41:28 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1990" NAME="Cohen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen M, Adams PC, Hawkins L, Bach M, Fuster V</AU>
<TI>Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group)</TI>
<SO>American Journal of Cardiology</SO>
<YR>1990</YR>
<VL>66</VL>
<NO>19</NO>
<PG>1287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1994" MODIFIED="2014-06-18 14:48:36 +0100" MODIFIED_BY="Heather Maxwell" NAME="Cohen 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-06-18 14:48:36 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al</AU>
<TI>Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users</TI>
<SO>Circulation</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>1</NO>
<PG>81-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doucet-2000" MODIFIED="2014-04-01 16:39:01 +0100" MODIFIED_BY="[Empty name]" NAME="Doucet 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-04-01 16:39:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doucet S, Malekianpour M, Theroux P, Bilodeau L, Cote G, Guise P, et al</AU>
<TI>Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>101</VL>
<NO>9</NO>
<PG>955-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FRISC-1996" NAME="FRISC 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swahn E, Wallentin L</AU>
<TI>Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC)</TI>
<SO>American College of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<PG>25E-29E</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wallentin L</AU>
<TI>Low-molecular-weight heparin during instability in coronary artery disease</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<NO>9001</NO>
<PG>561-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gurfinkel-1995" MODIFIED="2014-06-18 14:49:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Gurfinkel 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-06-18 14:49:22 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, et al</AU>
<TI>Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>2</NO>
<PG>313-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holdright-1994" NAME="Holdright 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, et al</AU>
<TI>Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1994</YR>
<VL>24</VL>
<NO>1</NO>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RISC-1990" NAME="RISC 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallentin L</AU>
<TI>Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8719</NO>
<PG>830-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Th_x00e9_roux-1988" MODIFIED="2014-06-18 15:41:28 +0100" MODIFIED_BY="Heather Maxwell" NAME="Théroux 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-06-18 15:41:28 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, et al</AU>
<TI>Aspirin, heparin, or both to treat acute unstable angina</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>319</VL>
<NO>17</NO>
<PG>1105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-06-24 12:26:56 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Averkov-1993" NAME="Averkov 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Averkov OV, Zateischikov DA, Gratsiansky NA, Logutov YA, Yavelov IS, Yanus VM</AU>
<TI>Unstable angina pectoris: aspirin and heparin in a double-blind placebo-controlled study, their effects on the outcojjme of disease during hospitalization</TI>
<SO>Kardiologiya</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>5</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bodo-1995" MODIFIED="2014-04-01 16:39:25 +0100" MODIFIED_BY="[Empty name]" NAME="Bodo 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-04-01 16:39:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bodo I, Nemeth C, Littmann L, Holdright DR, Fox KM</AU>
<TI>Heparin and aspirin in unstable angina: insufficient sample size may lead to erroneous conclusions</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>2</NO>
<PG>553-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borja-2000a" MODIFIED="2014-04-01 16:40:24 +0100" MODIFIED_BY="[Empty name]" NAME="Borja 2000a" YEAR="2000">
<REFERENCE MODIFIED="2014-04-01 16:40:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borja J, Olivella P</AU>
<TI>Low molecular weigh heparin in the treatment of acute coronary syndromes without ST elevation: Unstable angina and non Q wave myocardial infarction</TI>
<TO>Hepariona de bajo peso molecular en el tratamiento de los sindromes coronarios agudos sin elevacion del segmento ST: angina inestable e infarto de miocardio sin onda Q</TO>
<SO>Medicina Clinica</SO>
<YR>2000</YR>
<VL>115</VL>
<NO>15</NO>
<PG>583-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borja-2000b" NAME="Borja 2000b" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borja J, Campbell y Pere Olivella J, Magda H</AU>
<TI>Dalteparin in the acute phase of unstable angina and non-Q-wave infarction</TI>
<TO>Dalteparina en la fase cronica de la angina inestable e infarto sin onda Q</TO>
<SO>Revista Espanola de Cardiologia</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>8</NO>
<PG>1147-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borja-2000c" NAME="Borja 2000c" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borja J</AU>
<TI>Dalteparin for unstable angina and non-Q-wave myocardial infarction</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>20</NO>
<PG>3169-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1964" MODIFIED="2014-04-01 16:25:18 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 1964" YEAR="1964">
<REFERENCE MODIFIED="2014-04-01 16:25:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown KW, MacMillan RL</AU>
<TI>Initial heparin therapy in acute myocardial infarction</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1964</YR>
<VL>13</VL>
<NO>90</NO>
<PG>1345-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charvat-1989" NAME="Charvat 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charvat J, Kuruvilla T</AU>
<TI>Comparative study of heparin and antiplatelets in treatment of preinfarction angina</TI>
<SO>Cardiologia</SO>
<YR>1989</YR>
<VL>34</VL>
<PG>146-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1993" NAME="Cohen 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen M, Xiong J, Parry G, Adams PC, Chamberlain D, Wieczorek I, et al</AU>
<TI>Prospective comparison of unstable angina versus non-Q-wave myocardial infarction during antithrombotic therapy</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>5</NO>
<PG>1338-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2003" MODIFIED="2014-06-18 14:56:14 +0100" MODIFIED_BY="Heather Maxwell" NAME="Cohen 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-06-18 14:56:14 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, et al</AU>
<TI>The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1348-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-1996" NAME="Collins 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Baigent C, Peto R</AU>
<TI>Benefit of heparin plus aspirin vs aspirin alone in unstable angina</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>1873</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-COMPARE-2010" MODIFIED="2014-01-28 15:37:00 +0000" MODIFIED_BY="[Empty name]" NAME="COMPARE 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-01-28 15:37:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al</AU>
<TI>Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<NO>9710</NO>
<PG>201-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Correia-1995" MODIFIED="2014-04-01 16:40:58 +0100" MODIFIED_BY="[Empty name]" NAME="Correia 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-04-01 16:40:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Correia LC, Neubauer C, Azevedo A, Ribeiro F, Braga J, Passos LC, et al</AU>
<TI>The role of low molecular weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty</TI>
<TO>O papel da heparina de baixo peso do miocardio e pos-angioplastia percutanea transluminal coronaria eletiva.molecular na angina instavel, infarto agudo</TO>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1995</YR>
<VL>65</VL>
<NO>6</NO>
<PG>475-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CREATE-2005" MODIFIED="2014-01-28 15:38:41 +0000" MODIFIED_BY="[Empty name]" NAME="CREATE 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-01-28 15:38:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, et al</AU>
<TI>Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes inpatients with acute myocardial infarction presenting with ST-segment elevation</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>4</NO>
<PG>427-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FAMI-2000" NAME="FAMI 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Iyengar SS, De Lorenzo F, Hargreaves JR, Kadziola ZA</AU>
<TI>Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction</TI>
<SO>Indian Heart Journal</SO>
<YR>2000</YR>
<VL>52</VL>
<PG>533-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferguson-1999" MODIFIED="2014-06-18 14:57:43 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ferguson 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-06-18 14:57:43 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson JJ, Zaqqa M</AU>
<TI>Platelet Glycoprotein IIb/IIa receptor antagonists current concepts and future directions</TI>
<SO>Drugs</SO>
<YR>1999</YR>
<VL>58</VL>
<PG>965-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FRISC-II-1999" NAME="FRISC II 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ragmin F, Wallentin L, Swahn E, Kontny F, Husted S, Lagerqvist B, et al</AU>
<TI>Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9180</NO>
<PG>701-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujita-1988" NAME="Fujita 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A</AU>
<TI>Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina</TI>
<SO>Circulation</SO>
<YR>1988</YR>
<VL>77</VL>
<NO>5</NO>
<PG>1022-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GISSI_x002d_2-1990" NAME="GISSI-2 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feruglio GA, Lotto A, Rovelli F, Solinas P, Tavazzi L, Tognoni G, et al</AU>
<TI>GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8707</NO>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorski-1993" NAME="Gorski 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorski J, Dmochowska-Wroblewska W</AU>
<TI>Heparin in myocardial infarction and unstable angina</TI>
<TO>Kliniki Chorob Zawodowych i Tropikalnych Instytutu Medycyny Morskiej i Tropikalnej, Gdyni</TO>
<SO>Kardiologia Polska</SO>
<YR>1993</YR>
<VL>38</VL>
<NO>3</NO>
<PG>229-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goy-1999" NAME="Goy 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goy JJ</AU>
<TI>Contemporary approach to management of unstable angina</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>694-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gulba-1992" NAME="Gulba 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gulba DC</AU>
<TI>Heparin therapy in coronary heart disease</TI>
<TO>Heparin-therapie bei koronarer herzkrankheit</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1992</YR>
<VL>117</VL>
<NO>1</NO>
<PG>35-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasselblad-1998" NAME="Hasselblad 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasselblad V</AU>
<TI>Meta-analysis of multitreatment studies</TI>
<SO>Medical Decision Making</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-1989" NAME="Huber 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber K, Resch I, Rosc D, Probst P, Kaindl F, Binder BR</AU>
<TI>Heparin induced increase of T-PA antigen plasma levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment</TI>
<SO>Thrombosis Research</SO>
<YR>1989</YR>
<VL>55</VL>
<PG>779-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurtado-1984" NAME="Hurtado 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurtado L, Adabache M, Escarcega FL, Cardenas M</AU>
<TI>Acute myocardial infarction treated with anticoagulants</TI>
<TO>Evolucion hospitalaria del infarto agudo del miocardio tratado con y sin anticoagulantes</TO>
<SO>Archivos del Instituto de Cardiologia de Mexico</SO>
<YR>1984</YR>
<VL>54</VL>
<NO>5</NO>
<PG>463-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffrani-1993" NAME="Jaffrani 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffrani NA, Ehrenpreis S, Laddu A, Somberg J</AU>
<TI>Therapeutic approach to unstable angina: nitroglycerin, heparin, and combined therapy</TI>
<SO>American Heart Journal</SO>
<YR>1993</YR>
<VL>126</VL>
<PG>1239-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaul-2000" NAME="Kaul 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaul S, Shah PK</AU>
<TI>Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>35</VL>
<PG>1699-712</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kontny-2001" NAME="Kontny 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kontny F</AU>
<TI>Improving outcomes in acute coronary syndromes - the FRISC II trial</TI>
<SO>Clinical Cardiology</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>3 Suppl</NO>
<PG>I3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massel-2002" MODIFIED="2014-06-18 14:59:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Massel 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-06-18 14:59:22 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massel D, Cruickshank MK</AU>
<TI>Enoxaparin in acute coronary syndromes: Evidence for superiority over placebo or untreated control</TI>
<SO>American Heart Journal</SO>
<YR>2002</YR>
<VL>143</VL>
<NO>5</NO>
<PG>748-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattioli-1999" NAME="Mattioli 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattioli AV, Tarabini Castellani E, Goedecke L, Sormani L, Sternieri S, Mattioli G</AU>
<TI>Efficacy and tolerability of a very low molecular weight heparin compared with standard heparin in patients with unstable angina: a pilot study</TI>
<SO>Clinical Cardiology</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>3</NO>
<PG>213-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milonig_x002d_Ganner-1989" MODIFIED="2014-06-24 12:26:56 +0100" MODIFIED_BY="[Empty name]" NAME="Milonig-Ganner 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-06-24 12:26:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millonig-Gannjer</AU>
<TO>Koronarer bypass: erfolg hangt oft von psyche ab</TO>
<SO>Arch Medici Nr</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>433-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moise-1994" NAME="Moise 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moise A, Roos M</AU>
<TI>Aspirin versus heparin in the acute phase of unstable angina</TI>
<SO>Circulation</SO>
<YR>1994</YR>
<VL>90</VL>
<PG>1107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montgomery-1995" NAME="Montgomery 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery HE, Chester MR</AU>
<TI>Heparin in unstable angina</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<PG>248</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nardelli-1991" NAME="Nardelli 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nardelli A, Bottero G, De Francesco A</AU>
<TI>Study on the efficacy of heparin and aspirin in unstable angina and acute heart infarction</TI>
<TO>Cosa hanno insegnato i grandi trials sull'eparina e sull'aspirina nell'angina instablile e nell'infarto miocardico acuto</TO>
<SO>Clinica e Terapia Cardiovascolare</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>3</NO>
<PG>171-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-OASIS_x002d_6-2006" MODIFIED="2014-04-01 16:41:51 +0100" MODIFIED_BY="[Empty name]" NAME="OASIS-6 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-01 16:41:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al</AU>
<TI>Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>13</NO>
<PG>1519-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ocampo-1998" MODIFIED="2014-06-18 15:21:37 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ocampo 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-06-18 15:21:37 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ocampo S, Solorio S, Rangel A, Leon FJ, Lepe L, Ayala F, et al</AU>
<TI>Low molecular weight heparin in unstable angina pectoris</TI>
<TO>La heparina de bajo peso molecular en la angina de pecho inestable</TO>
<SO>Archivos del Instituto de Cardiologia de Mexico</SO>
<YR>1999</YR>
<VL>69</VL>
<PG>222-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oldgren-2008" MODIFIED="2014-04-01 16:42:06 +0100" MODIFIED_BY="[Empty name]" NAME="Oldgren 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-01 16:42:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oldgren J, Wallentin L, Afzal R, Bassand JP, Budaj A, Chrolavicius S, et al</AU>
<TI>Effects of fondaparinux in patients withST-segment elevation acute myocardial infarction not receiving reperfusion treatment</TI>
<SO>European Heart Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>3</NO>
<PG>315-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oler-1996" MODIFIED="2014-04-01 16:42:15 +0100" MODIFIED_BY="[Empty name]" NAME="Oler 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-04-01 16:42:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oler A, Whooley MA, Oler J, Grady D</AU>
<TI>Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>811-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peterson-2001" MODIFIED="2014-04-01 16:28:30 +0100" MODIFIED_BY="[Empty name]" NAME="Peterson 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-01 16:28:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peterson JG, Topol EJ, Roe MT, Sapp SK, Lincoff AM, Deckers JW, et al</AU>
<TI>Prognostic Importance of ConcomitantHeparin With Eptifibatide in AcuteCoronary Syndromes</TI>
<SO>American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>5</NO>
<PG>532-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PURSUIT-2001" NAME="PURSUIT 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, et al</AU>
<TI>Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>23</NO>
<PG>2772-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raschke-1993" NAME="Raschke 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S</AU>
<TI>The weight-based heparin dosing nomogram compared with a "standard care" nomogram</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>874-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio_x002d_Terres-2001" NAME="Rubio-Terres 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio-Terres C, Pajuelo F, Margalet I</AU>
<TI>Low-molecular-weight heparins in unstable angina and non-Q-wave myocardial infarction</TI>
<TO>Heparinas de bajo peso molecular en la angina inestable y el infarto de miocardio sin onda Q</TO>
<SO>Medicina Clinica</SO>
<YR>2001</YR>
<VL>116</VL>
<NO>16</NO>
<PG>638-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sayen-1982" MODIFIED="2014-04-01 16:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Sayen 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-04-01 16:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sayen JJ, Singer RB, Peirce G, Horwitz O</AU>
<TI>Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20,000 units/day) in the treatment of patients with acute coronary event - first year and long-term comparative mortality</TI>
<SO>Transactions of the American Clinical &amp; Climatological Association</SO>
<YR>1982</YR>
<VL>94</VL>
<PG>141-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serneri-1988" NAME="Serneri 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serneri GGN, Abbate R, Prisco D, Carnovali M, Fazi A, Casolo GC, et al</AU>
<TI>Decrease in frequency of anginal episodes by control of thrombin generation with low-dose heparin: a controlled cross-over randomized study</TI>
<SO>American Heart Journal</SO>
<YR>1988</YR>
<VL>115</VL>
<PG>60-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serneri-1990" MODIFIED="2014-04-01 16:42:58 +0100" MODIFIED_BY="[Empty name]" NAME="Serneri 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-01 16:42:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serneri GGN, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, et al</AU>
<TI>Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>615-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serneri-1995" MODIFIED="2014-06-18 15:24:53 +0100" MODIFIED_BY="Heather Maxwell" NAME="Serneri 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-06-18 15:24:53 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serneri GGN, Modesti PA, Gensini GF, Branzi A, Melandri G, Poggesi L, et al</AU>
<TI>Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<NO>8959</NO>
<PG>1201-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spodick-1989" NAME="Spodick 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spodick DH</AU>
<TI>Aspirin, heparin, or both to treat unstable angina</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<PG>1014</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanajura-1993" MODIFIED="2014-06-18 15:37:49 +0100" MODIFIED_BY="Heather Maxwell" NAME="Tanajura 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-06-18 15:37:49 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanajura LFL, Sousa AGMR, Pinto IMF, Chaves AJ, Centemero MP, Feres F, et al</AU>
<TI>Use of heparin in coronary angioplasty: randomized trial in low risk patients for abrupt closure</TI>
<TO>Heparina na Angioplastia Coronária. Estudo Randomizado emCasos com Baixo Risco Para Oclusão Aguda</TO>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1993</YR>
<VL>60</VL>
<NO>2</NO>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TETAMI--2000" NAME="TETAMI  2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen M, Maritz F, Gensini GF, Danchin N, Timerman A, Huber K, et al</AU>
<TI>The TETAMI Trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design</TI>
<SO>Journal of Thrombosis &amp; Thrombolysis</SO>
<YR>2000</YR>
<VL>10</VL>
<PG>241-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Th_x00e9_roux-1993" MODIFIED="2014-06-18 15:43:15 +0100" MODIFIED_BY="Heather Maxwell" NAME="Théroux 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-06-18 15:42:58 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Théroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M</AU>
<TI>Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina</TI>
<SO>Circulation</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>5 Pt 1</NO>
<PG>2045-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thieuleux-1985" NAME="Thieuleux 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thieuleux FA, Vilarem D, Lablanche JM, Asseman PA, Thery C, Bertrand ME</AU>
<TI>Management of unstable angina pectoris with maximal medical treatment (combination of intravenous nitrates, beta-blockers, calcium antagonists and heparin)</TI>
<SO>Bibliotheca Cardiologica</SO>
<YR>1985</YR>
<VL>39</VL>
<PG>88-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Umans-1997" NAME="Umans 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Umans VA, Kloeg PH, Bronzwaer J</AU>
<TI>The CAPTURE trial</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>445</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Violaris-1991" MODIFIED="2014-04-01 16:43:11 +0100" MODIFIED_BY="[Empty name]" NAME="Violaris 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-04-01 16:43:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Violaris AG, Campbell S</AU>
<TI>Low-dose aspirin and heparin in unstable coronary artery disease</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>489-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallentin-1997" NAME="Wallentin 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallentin L, Husted S, Kontny F</AU>
<TI>Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II study)</TI>
<SO>American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>80</VL>
<PG>61E-63E</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallis-1991" NAME="Wallis 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallis DE, Boden WE, Califf R, Crawford MH, Hakki AH, Iskandrian AS, et al</AU>
<TI>Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina</TI>
<SO>American Heart Journal</SO>
<YR>1991</YR>
<VL>122</VL>
<PG>949-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-02-02 19:43:25 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Zwerner-1987" MODIFIED="2014-02-02 19:43:25 +0000" MODIFIED_BY="[Empty name]" NAME="Zwerner 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwerner P, Gore J, Corrao J, et al</AU>
<TI>Heparin in the treatment of unstable angina: a randomized prospective trial</TI>
<SO>Circulation</SO>
<YR>1987</YR>
<VL>76</VL>
<NO>Suppl IV</NO>
<PG>IV-180</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-06-18 16:04:52 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2014-06-18 16:04:52 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-ACCF_x002f_AHA-Guideline-NSTEACS-2013" MODIFIED="2014-02-02 22:46:15 +0000" MODIFIED_BY="[Empty name]" NAME="ACCF/AHA Guideline NSTEACS 2013" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JL, Adams CD, Antman EM, Bridges CR, CaliffRM, Casey DE Jr, et al</AU>
<TI>2012 ACCF/AHA focused update incorporated into the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force onPractice Guidelines</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2013</YR>
<VL>61</VL>
<NO>23</NO>
<PG>e179&#8211;347</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-1995" MODIFIED="2014-04-01 03:39:58 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al</AU>
<TI>One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>7</NO>
<PG>1643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowry-2008" MODIFIED="2014-04-24 18:22:24 +0100" MODIFIED_BY="[Empty name]" NAME="Bowry 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bowry AD, Brookhart MA, Choudhry NK</AU>
<TI>Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events</TI>
<SO>American Journal of Cardiology</SO>
<YR>2008</YR>
<VL>101</VL>
<NO>7</NO>
<PG>960-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cairns-1989" MODIFIED="2014-06-18 15:50:57 +0100" MODIFIED_BY="Heather Maxwell" NAME="Cairns 1989" TYPE="JOURNAL_ARTICLE">
<AU>Cairns JA, J Singer, M Gent, Holder DA, Rogers D, Sackett DL, et al</AU>
<TI>One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or chest pain in Hamilton, Ontario, a city of 375,000 people</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>1989</YR>
<VL>319</VL>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1998" MODIFIED="2008-09-08 22:59:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Cohen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cohen M</AU>
<TI>Approaches to the treatment of unstable angina and non-Q wave myocardial infarction</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>1998</YR>
<VL>14</VL>
<NO>Suppl E</NO>
<PG>11E-14E</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1987" MODIFIED="2014-04-01 03:40:30 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1987" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eikelboom-2000" MODIFIED="2014-04-01 02:56:40 +0100" MODIFIED_BY="[Empty name]" NAME="Eikelboom 2000" TYPE="JOURNAL_ARTICLE">
<AU>Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S</AU>
<TI>Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9219</NO>
<PG>1936-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESC-Guidelines-NSTEACS-2011" MODIFIED="2014-04-01 02:55:23 +0100" MODIFIED_BY="[Empty name]" NAME="ESC Guidelines NSTEACS 2011" TYPE="JOURNAL_ARTICLE">
<AU>Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al</AU>
<TI>ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)</TI>
<SO>European Heart Journal</SO>
<YR>2011</YR>
<VL>32</VL>
<NO>23</NO>
<PG>2999-3054</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eshaghian-2007" MODIFIED="2014-04-24 18:20:47 +0100" MODIFIED_BY="[Empty name]" NAME="Eshaghian 2007" TYPE="JOURNAL_ARTICLE">
<AU>Eshaghian S, Kaul S, Amin S, Shah PK, Diamond GA</AU>
<TI>Role of clopidogrel in managing atherothrombotic cardiovascular disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<NO>6</NO>
<PG>434-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falk-1995" MODIFIED="2014-04-01 02:45:15 +0100" MODIFIED_BY="[Empty name]" NAME="Falk 1995" TYPE="JOURNAL_ARTICLE">
<AU>Falk E, Shah P, Fuster V</AU>
<TI>Coronary plaque disruption</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>3</NO>
<PG>657-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-09-08 22:59:05 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deek JJ, Altman DG</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test.</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-02-02 19:27:19 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Intervention</SO>
<YR>2011</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-1998" MODIFIED="2014-06-18 15:53:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hirsh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE</AU>
<TI>Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>489S-510S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-1983" MODIFIED="2014-06-18 15:55:39 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lewis 1983" TYPE="JOURNAL_ARTICLE">
<AU>Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, et al</AU>
<TI>Proctective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results for a Veterans Administration Cooperative Study</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>7</NO>
<PG>396-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Libby-2002" MODIFIED="2008-09-08 22:59:04 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Libby 2002" TYPE="JOURNAL_ARTICLE">
<AU>Libby P, Ridker PM, Maseri A</AU>
<TI>Inflammation and atherosclerosis</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>105</VL>
<PG>1135-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magee-2003" MODIFIED="2008-09-08 22:59:05 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Magee 2003" TYPE="COCHRANE_REVIEW">
<AU>Magee KD, Sevcik W, Moher D, Rowe BH</AU>
<TI>Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002132"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manoukian-2007" MODIFIED="2014-04-01 03:40:56 +0100" MODIFIED_BY="[Empty name]" NAME="Manoukian 2007" TYPE="JOURNAL_ARTICLE">
<AU>Manoukian SV, Voeltz MD, Eikelboom J</AU>
<TI>Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk</TI>
<SO>Clinical Cardiology</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>2</NO>
<PG>II24-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2014-04-01 18:30:57 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TIMI-IIIB-1994" MODIFIED="2014-04-01 02:50:22 +0100" MODIFIED_BY="[Empty name]" NAME="TIMI IIIB 1994" TYPE="JOURNAL_ARTICLE">
<AU>The TIMI IIIB Investigators</AU>
<TI>Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia</TI>
<SO>Circulation</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>4</NO>
<PG>1545-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warkentin-2003" MODIFIED="2014-06-18 15:56:46 +0100" MODIFIED_BY="Heather Maxwell" NAME="Warkentin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Warkentin TE, Roberts RS, Hirsh J, Kelton JG</AU>
<TI>An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>20</NO>
<PG>2518-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weitz-1997" MODIFIED="2014-04-01 16:43:56 +0100" MODIFIED_BY="[Empty name]" NAME="Weitz 1997" TYPE="JOURNAL_ARTICLE">
<AU>Weitz JE</AU>
<TI>Low molecular weight heparins</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>688-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-2001" MODIFIED="2014-06-18 16:04:34 +0100" MODIFIED_BY="Heather Maxwell" NAME="Yusuf 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators</AU>
<TI>Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>7</NO>
<PG>494-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-2012" MODIFIED="2014-06-18 16:04:52 +0100" MODIFIED_BY="Heather Maxwell" NAME="Zhou 2012" TYPE="JOURNAL_ARTICLE">
<AU>Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF, et al</AU>
<TI>Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis</TI>
<SO>PloS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>2</NO>
<PG>e316242</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-18 15:46:17 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Magee-2008" MODIFIED="2014-06-18 15:46:17 +0100" MODIFIED_BY="Heather Maxwell" NAME="Magee 2008" TYPE="COCHRANE_REVIEW">
<AU>Magee K, Campbell SG, Moher D, Rowe BH</AU>
<TI>Heparin versus placebo for acute coronary syndromes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-06-18 15:46:06 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2014-06-18 15:46:06 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003462.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-06-19 20:51:53 +0100" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-06-19 20:51:53 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-06-19 20:08:18 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cohen-1990">
<CHAR_METHODS MODIFIED="2013-12-07 19:33:32 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomized, open-label trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-11 04:15:00 +0000" MODIFIED_BY="[Empty name]">
<P>93 patients (21-75 years old) with unstable angina or NSTEMI. Chest pain occurring within 48 hours of randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-19 11:17:45 +0100" MODIFIED_BY="Heather Maxwell">
<P>3 treatment groups,</P>
<P>Group 1: ASA alone 325 mg (bolus and daily [same dose]) (n = 32)</P>
<P>Group 2: Heparin infusion (loading 100 U/kg, then infusion to maintain aPTT at two times control) + warfarin started on day 3 or 4 to maintain INR 2-3 (n = 24)</P>
<P>Group 3: ASA (325 mg bolus, then 80 mg daily) + heparin + warfarin (n = 37)</P>
<P>Intended duration of heparin infusion was 3-4 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-07 19:34:24 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes at 12 weeks.</P>
<P>Primary outcome: recurrent angina, MI, death</P>
<P>Secondary outcomes: major/minor bleeding, revascularization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-19 20:08:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>ASA vs ASA + UFH/warfarin. Used data from group 1 and 3 only.</P>
<P>Trial therapy was continued for 12 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 11:18:11 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cohen-1994">
<CHAR_METHODS MODIFIED="2013-12-07 19:35:08 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomized, open-label, multicenter.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-18 16:24:00 +0100" MODIFIED_BY="Heather Maxwell">
<P>214 patients (&gt; 21 years old) with unstable angina or NSTEMI. Chest pain occurring within 48 hours of randomization.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-19 11:18:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>2 treatment groups,</P>
<P>Group 1: ASA alone 162.5 mg (bolus and daily [same dose]) (n = 109)</P>
<P>Group 2: ASA + heparin infusion (loading 100 U/kg, then infusion to maintain aPTT at two times control) + warfarin started on day 3 or 4 to maintain INR 2-3 <B>(</B>n = 105<B>)</B>
</P>
<P>Intended duration of heparin infusion was 3-4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-07 19:36:21 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome (hospital discharge to 12 weeks): recurrent angina, MI, death.</P>
<P>Secondary outcomes: major bleeding, revascularization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-07 19:36:33 +0000" MODIFIED_BY="[Empty name]">
<P>ASA vs ASA + UFH/warfarin.</P>
<P>Trial therapy was continued for 12 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 11:18:32 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Doucet-2000">
<CHAR_METHODS MODIFIED="2013-12-11 04:15:24 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, 2 x 2 factorial double-blind, placebo-controlled, randomized trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-07 19:37:21 +0000" MODIFIED_BY="[Empty name]">
<P>200 patients hospitalized for unstable angina within 2 weeks to 6 months after angioplasty (excluding those with intracoronary stents).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-19 11:18:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>4 treatment groups, ASA 325 mg/d + one of;</P>
<P>Group 1: intravenous nitroglycerin infusion + placebo UFH (n = 47)</P>
<P>Group 2: intravenous UFH (heparin bolus followed by infusion) + placebo nitroglycerin (n = 48)</P>
<P>Group 3: intravenous nitroglycerin + intravenous UFH (n = 48)</P>
<P>Group 4: placebo nitroglycerin + placebo UFH (n = 48)</P>
<P>96 patient received UFH + ASA</P>
<P>95 patients received ASA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-07 19:38:00 +0000" MODIFIED_BY="[Empty name]">
<P>Primary end point: Recurrence of angina at 63+/-30 hours.</P>
<P>Safety outcome: serious bleeding (need for transfusion or a fall in hemoglobin of &#8805;2 g/L).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-18 16:25:11 +0100" MODIFIED_BY="Heather Maxwell">
<P>Unstable angina was defined as recurrent or increased frequency of chest pain lasting &gt; 5 minutes at rest or with minimal exertion within 24 hours before randomization. In the absence of ischemic ECG, inclusion required independent confirmation of the diagnosis of unstable angina by 2 cardiologists.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 20:07:31 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-FRISC-1996">
<CHAR_METHODS MODIFIED="2014-06-19 20:07:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prospective, multicenter double-blind, randomized, placebo-controlled, parallel-group trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-07 19:39:07 +0000" MODIFIED_BY="[Empty name]">
<P>1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction)</P>
<P>admitted to hospital with chest pain within the previous 72 hours.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-18 16:25:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>2 treatment groups, ASA 300 mg/d (then 75 mg) + one of;</P>
<P>Group 1: dalteparin 120 IU/kg SC twice daily x 6 days, then 7500 IU daily for 35-45 days.</P>
<P>Group 2: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-01 16:36:32 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Difference in the rate of death, new MI during the first 6 days of treatment (acute phase).</P>
<P>Secondary outcomes: death and MI after 35-45 days, revascularization procedures, major/minor bleeding, thrombocytopenia and need for IV heparin (nIVH).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-07 19:39:58 +0000" MODIFIED_BY="[Empty name]">
<P>Acute phase data used for death and MI outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 11:18:47 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gurfinkel-1995">
<CHAR_METHODS>
<P>Prospective, randomized, single-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-07 19:40:39 +0000" MODIFIED_BY="[Empty name]">
<P>211 patients (&gt;21 years old) with unstable angina</P>
<P>occurring within 24 hours of randomization.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-19 11:18:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>3 treatment groups, ASA 200 mg/d + one of;</P>
<P>Group 1: ASA + placebo heparin (n = 73)</P>
<P>Group 2: ASA + heparin infusion (400 IU/kg body weight per day) preceded by a bolus (5,000 IU) (n = 70)</P>
<P>Group 3: ASA + subcutaneous nadroparin calcium (214 [UIC]/kg anti-Xa sc bid) + placebo heparin (n = 68)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-07 19:41:13 +0000" MODIFIED_BY="[Empty name]">
<P>In-hospital period or if a primary end point reached (5-7 days)</P>
<P>Primary outcome: Recurrent angina, death, MI, urgent revascularization major/minor bleeding, thrombocytopenia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-18 16:27:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>Split control group. Patients had evidence of underlying ischemic heart disease. Analysis was based on intention-to-treat.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 11:18:58 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Holdright-1994">
<CHAR_METHODS MODIFIED="2014-06-18 16:27:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prospective, randomized, single-blind multicenter trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-07 19:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>285 patients (30-75 years old) with unstable angina</P>
<P>occurring within 24 hours of randomization.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-19 11:18:58 +0100" MODIFIED_BY="Heather Maxwell">
<P>2 treatment groups, ASA 150 mg/d + one of;</P>
<P>Group 1: ASA (n = 131)</P>
<P>Group 2: ASA + heparin infusion (bolus 5,000 IU, then infusion to maintain aPTT 1.5-2.5 the baseline) (n = 154)</P>
<P>Intended duration of heparin infusion was 48 hrs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-07 19:42:45 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes over the duration of the hospital admission.</P>
<P>Primary outcome: transient MI, MI, death, revascularization.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-07 19:42:55 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome &#8220;MI or death&#8221; comes together. Mean duration of hospital stay 7.7 days.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 20:08:25 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-RISC-1990">
<CHAR_METHODS MODIFIED="2014-06-19 20:07:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prospective, randomized, double-blind, placebo-controlled multicenter trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-07 19:43:23 +0000" MODIFIED_BY="[Empty name]">
<P>796 patients (&lt;70 years old) with unstable angina or NSTEMI. Chest pain</P>
<P>occurring within previous 4 weeks (randomized to treatment up to 72 hours after admission).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-19 11:19:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>4 treatment groups,</P>
<P>Group 1: ASA placebo + UFH placebo</P>
<P>Group 2: ASA placebo + UFH 5000 U IV 6 hourly x 1 day, then 3750 IV 6 hourly x 4 days</P>
<P>Group 3: ASA 75 mg/d + UFH placebo (n = 189)</P>
<P>Group 4: ASA 75 mg/d + UFH (same as group 2) (n = 210)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-07 19:43:52 +0000" MODIFIED_BY="[Empty name]">
<P>Outcomes at 5 days, 30 days and 90 days.</P>
<P>Primary outcome: Death or MI (90 days), revascularization,</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-19 20:08:25 +0100" MODIFIED_BY="Heather Maxwell">
<P>Only used data from groups 3 and 4.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-19 11:19:22 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Th_x00e9_roux-1988">
<CHAR_METHODS MODIFIED="2014-06-18 16:28:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>Prospective, randomized, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-07 19:44:40 +0000" MODIFIED_BY="[Empty name]">
<P>479 patients with unstable angina (admitted or while hospitalized), within 24 hours preceding the time of randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-19 11:19:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>4 treatment groups (6 days of therapy),</P>
<P>Group 1: ASA 650 mg, then 325 mg bid + UFH placebo (n = 121)</P>
<P>Group 2: UFH 5000 U, then 1000 U/hour + placebo ASA</P>
<P>Group 3: ASA 650 mg, then 325 mg bid + UFH 5000 U IV, then 1000 U/hour (n = 122)</P>
<P>Group 4: placebo + placebo UFH</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-07 19:45:09 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome (6 days and 3 months): refractory angina, MI, death, serious (major) bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study was discontinued prematurely on the basis of first interim data analysis. Use only data from Groups 1 and 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>aPTT - activated partial thromboplastin time<BR/>ASA - aspirin<BR/>CAD - coronary artery disease<BR/>INR - international normalized ratio<BR/>IV - intravenous<BR/>MI - myocardial infarction<BR/>NSTEMI - non-ST segment myocardial infarction<BR/>SC - subcutaneous<BR/>UFH - unfractionated heparin<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-18 16:15:53 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Averkov-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients treated with ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:06:24 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bodo-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:06:24 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:06:28 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Borja-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:06:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:06:35 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Borja-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:06:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:06:52 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Borja-2000c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:06:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:11:02 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Brown-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:11:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>Patients had ST-segment elevation MI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Charvat-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients treated with ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:15:53 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cohen-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:15:53 +0100" MODIFIED_BY="Heather Maxwell">
<P>Unclear from results to which study group participants had been randomized. Attempts to communicate with authors unsuccessful.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-28 15:43:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-28 15:43:35 +0000" MODIFIED_BY="[Empty name]">
<P>Heparin not compared versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:08:53 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Collins-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:08:53 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-28 15:42:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-COMPARE-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-28 15:42:34 +0000" MODIFIED_BY="[Empty name]">
<P>Patients not compared to placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Correia-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients not compared to placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:11:12 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-CREATE-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:11:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Patients had ST-segment elevation MI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-FAMI-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group in the acute phase of the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:09:48 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ferguson-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:09:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-FRISC-II-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients randomized greater than 72 hrs after most recent chest pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fujita-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not the research question</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:11:19 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-GISSI_x002d_2-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:11:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>Patients had ST-segment elevation MI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:10:08 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gorski-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:10:08 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:10:17 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Goy-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:10:17 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:10:28 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gulba-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:10:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:10:36 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Hasselblad-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:10:36 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huber-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients treated with ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hurtado-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had ST-segment elevation MI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:11:29 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Jaffrani-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:11:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:11:36 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kaul-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:11:36 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:11:42 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kontny-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:11:42 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:11:49 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Massel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:11:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattioli-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Heparin not compared versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:12:01 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Milonig_x002d_Ganner-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:12:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:12:13 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Moise-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:12:13 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:12:18 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Montgomery-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:12:18 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:12:28 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Nardelli-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:12:28 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-28 15:44:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-OASIS_x002d_6-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-28 15:44:44 +0000" MODIFIED_BY="[Empty name]">
<P>Patients had ST-segment elevation MI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ocampo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Heparin not compared versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:12:48 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Oldgren-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:12:48 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:12:54 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Oler-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:12:54 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:13:00 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Peterson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:13:00 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-PURSUIT-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not the study question</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raschke-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not the study question</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:13:13 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rubio_x002d_Terres-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:13:13 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:13:19 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sayen-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:13:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serneri-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outpatient setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serneri-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients treated with ASA; only inpatients were admitted into the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serneri-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients treated with ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:13:35 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Spodick-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:13:35 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-28 15:46:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tanajura-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-28 15:46:36 +0000" MODIFIED_BY="[Empty name]">
<P>Outpatient setting, no patients with acute coronary syndromes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:13:49 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-TETAMI--2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:13:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:13:58 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Thieuleux-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:13:58 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Th_x00e9_roux-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients treated with ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:14:09 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Umans-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:14:09 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:14:16 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Violaris-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:14:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:14:22 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Wallentin-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:14:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-18 16:14:30 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Wallis-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-18 16:14:30 +0100" MODIFIED_BY="Heather Maxwell">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ASA - aspirin<BR/>MI - myocardial infarction</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Zwerner-1987">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-06-19 20:50:52 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-12-22 23:57:52 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:00:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1990">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:01:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:03:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Doucet-2000">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:55:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FRISC-1996">
<DESCRIPTION>
<P>Randomization done in blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:56:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gurfinkel-1995">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:57:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holdright-1994">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:06:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RISC-1990">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:04:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Th_x00e9_roux-1988">
<DESCRIPTION>
<P>Randomization done in blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-06-18 16:25:24 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:00:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1990">
<DESCRIPTION>
<P>Method of concealment not described. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:01:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION>
<P>Method of concealment not described. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-18 16:25:24 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Doucet-2000">
<DESCRIPTION>
<P>Central allocation (pharmacy-controlled randomization).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-08 18:12:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FRISC-1996">
<DESCRIPTION>
<P>Quote: &#8220;Placebo was packaged in matching ampoules and syringes&#8221; (identical appearance) but, they don&#8217;t describe the method of concealment in sufficient detail (it´s unclear if they were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:56:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gurfinkel-1995">
<DESCRIPTION>
<P>Method of concealment not described. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:57:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holdright-1994">
<DESCRIPTION>
<P>Method of concealment not described. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:06:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RISC-1990">
<DESCRIPTION>
<P>Method of concealment not described. Probably not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:05:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Th_x00e9_roux-1988">
<DESCRIPTION>
<P>Pharmacy-controlled randomization (central)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-12-21 17:59:14 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-06-19 20:50:52 +0100" MODIFIED_BY="Heather Maxwell" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-12-21 18:00:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cohen-1990">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-12-21 18:02:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-12-21 18:03:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doucet-2000">
<DESCRIPTION>
<P>Blinding of participants and personnel. They used coded medications prepared by the hospital pharmacists. aPTT results know only to the pharmacists (infusion rates of placebo were also modified to maintain blinding).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-12-22 23:55:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FRISC-1996">
<DESCRIPTION>
<P>Blinding of participants and personnel likely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-12-22 23:56:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gurfinkel-1995">
<DESCRIPTION>
<P>Single-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-12-22 23:58:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holdright-1994">
<DESCRIPTION>
<P>Single-blind trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-06-19 20:50:52 +0100" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-RISC-1990">
<DESCRIPTION>
<P>Trial labeled as &#8220;double-blind&#8221; but the study did not address this further</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-02-08 18:11:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Th_x00e9_roux-1988">
<DESCRIPTION>
<P>Blinding probably ensured.</P>
<P>Quote: &#8220;trial medication prepackaged and coded by the pharmacists on a randomized, double-blind basis&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-04-01 16:37:27 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-21 18:00:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cohen-1990">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-21 18:02:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-21 18:03:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Doucet-2000">
<DESCRIPTION>
<P>This study did not address this outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-22 23:55:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-FRISC-1996">
<DESCRIPTION>
<P>This study did not address this outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-22 23:57:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gurfinkel-1995">
<DESCRIPTION>
<P>This study did not address this outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-08 18:12:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holdright-1994">
<DESCRIPTION>
<P>This study did not address this outcome. </P>
<P>Quote: &#8220;all data were analysed centrally&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-21 18:06:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-RISC-1990">
<DESCRIPTION>
<P>The study did not address this outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-01 16:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Th_x00e9_roux-1988">
<DESCRIPTION>
<P>Some key study personnel probably not blinded, but, outcome measurement are not likely to be influenced by the lack of blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-02-08 18:12:06 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-21 18:01:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1990">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-21 18:02:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-21 18:03:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doucet-2000">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-22 23:55:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FRISC-1996">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across groups (follow-up was incomplete in 8 patients [5 dalteparin, 3 placebo]).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-22 23:57:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gurfinkel-1995">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-22 23:58:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holdright-1994">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-08 18:12:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RISC-1990">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across groups. </P>
<P>Quote: &#8220;After 3 months, 95% of patients remained on treatment with no difference between the aspirin and placebo groups&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-21 18:05:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Th_x00e9_roux-1988">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-12-22 23:58:40 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:01:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1990">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:03:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doucet-2000">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:56:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FRISC-1996">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:57:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gurfinkel-1995">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:58:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holdright-1994">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:07:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RISC-1990">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:05:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Th_x00e9_roux-1988">
<DESCRIPTION>
<P>No protocol available, all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-01-11 04:18:09 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:00:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:01:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:03:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Doucet-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:55:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-FRISC-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:57:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gurfinkel-1995">
<DESCRIPTION>
<P>Trial stopped early (interim analysis revealed benefit with nadroparin and more bleeding with heparin).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-22 23:57:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holdright-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-21 18:07:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-RISC-1990">
<DESCRIPTION>
<P>Early conclusion of the study recommended by the safety committee, the follow-up was planned for 1 year (it was reduced to 3 months), probably not a risk of bias for this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-11 04:18:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Th_x00e9_roux-1988">
<DESCRIPTION>
<P>The study was discontinued prematurely on the basis of the policy board recommendation after the first interim data analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-04-25 02:59:06 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-04-25 02:59:06 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-04-01 18:34:36 +0100" MODIFIED_BY="[Empty name]">Heparin versus placebo for non-ST elevation acute coronary syndromes</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>Heparin versus placebo for non-ST elevation acute coronary syndromes</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with non-ST elevation acute coronary syndromes<BR/>
<B>Settings:</B> Inpatients<BR/>
<B>Intervention:</B> Heparin<BR/>
<B>Comparison: </B>Placebo or untreated control</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ASA</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Heparin + ASA</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
<BR/>Follow-up: 5-150 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.84 </B>
<BR/>(0.36 to 1.98)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2426<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Low due to study limitations and imprecision</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
<BR/>(3 to 18)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Incidence of myocardial infarction</B>
<BR/>Follow-up: 5-150 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.4 </B>
<BR/>(0.25 to 0.63)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2426<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Low quality because of very serious study limitations</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
<BR/>(12 to 30)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>58 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
<BR/>(15 to 37)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Recurrent angina</B>
<BR/>Follow-up: 5-150 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.81 </B>
<BR/>(0.6 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2426<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Very low due to study limitations and inconsistency</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>166 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>134 per 1000</B>
<BR/>(99 to 181)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>361 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>292 per 1000</B>
<BR/>(217 to 393)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Incidence of revascularization procedures</B>
<BR/>Follow-up: 5-150 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.93 </B>
<BR/>(0.76 to 1.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2520<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Low quality because of very serious study limitations</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>96 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
<BR/>(73 to 111)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>135 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>126 per 1000</B>
<BR/>(103 to 155)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Major hemorrhage</B>
<BR/>Follow-up: 2-150 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.05 </B>
<BR/>(0.91 to 4.6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>3118<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Low quality because of very serious study limitations</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
<BR/>(4 to 21)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants and outcome assessors in two trials, blinding of outcome assessors is uncertain in three trials. Final decision: rate down by one level (lack of blinding not considered a serious study limitation for the outcome of all-cause mortality). Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit.<BR/>
<SUP>2</SUP> Wide confidence intervals and few events. We decided to rate down for imprecision because confidence intervals fails to exclude important benefit or important harm.<BR/>
<SUP>3</SUP> Funnel plot could be interpreted as suggesting of publication bias. However, the number of studies is insufficient to meet rigorous criteria for creating a funnel plot. Final decision: publication bias is speculative (not rate down).<BR/>
<SUP>4</SUP> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants in four trials, lack of blinding of outcome assessors in two trials, blinding of outcome assessors is uncertain in three trials. Final decision: rate down by two levels.Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit.<BR/>
<SUP>5</SUP> Allocation concealment was uncertain in the majority of the evaluated trials. Lack of blinding of participants in four trials, lack of blinding of outcome assessors in two trials, blinding of outcome assessors is uncertain in five trials. Final decision: rate down by two levels.Two trials stopped early for benefit; stopping early as a source of bias is questionable. Final decision was not to rate down for stopping early for benefit.</P>
<P>
<SUP>6</SUP> Results were inconsistent across studies as evidenced by I² = 65%</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-04-25 03:47:59 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-04-25 03:45:07 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Incidence of death over all time periods</NAME>
<DICH_OUTCOME CHI2="0.3874494185216189" CI_END="1.982760612186487" CI_START="0.359459995999156" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8442293063639988" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.29727028299891545" LOG_CI_START="-0.4443494348597544" LOG_EFFECT_SIZE="-0.07353957593041952" METHOD="MH" MODIFIED="2014-04-25 03:45:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8238847430750229" P_Q="0.8243039469105167" P_Z="0.6974958325114724" Q="0.3864320475727386" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1238" TOTAL_2="1188" WEIGHT="100.00000000000001" Z="0.38870304224958213">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.452577802674449" CI_START="0.3257981814126967" DF="0" EFFECT_SIZE="0.8938933873144399" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.38962279331446903" LOG_CI_START="-0.4870513442283535" LOG_EFFECT_SIZE="-0.04871427545694219" NO="1" P_CHI2="1.0" P_Z="0.827569991945021" STUDIES="2" TAU2="0.0" TOTAL_1="809" TOTAL_2="793" WEIGHT="69.527802072966" Z="0.2178191903691385">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="2.452577802674449" CI_START="0.3257981814126967" EFFECT_SIZE="0.8938933873144399" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.38962279331446903" LOG_CI_START="-0.4870513442283535" LOG_EFFECT_SIZE="-0.04871427545694219" ORDER="1449" O_E="0.0" SE="0.5149627279996231" STUDY_ID="STD-FRISC-1996" TOTAL_1="741" TOTAL_2="757" VAR="0.2651866112288138" WEIGHT="69.527802072966"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1450" O_E="0.0" SE="0.0" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.036705211058344" CI_START="0.013601565287485037" DF="0" EFFECT_SIZE="0.33062330623306235" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.9050780385582232" LOG_CI_START="-1.8664111095268476" LOG_EFFECT_SIZE="-0.4806665354843121" NO="2" P_CHI2="1.0" P_Z="0.49660372113020423" STUDIES="3" TAU2="0.0" TOTAL_1="287" TOTAL_2="254" WEIGHT="13.230991947401758" Z="0.6798432523351726">
<NAME>UFH</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1451" O_E="0.0" SE="0.0" STUDY_ID="STD-Doucet-2000" TOTAL_1="95" TOTAL_2="96" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1452" O_E="0.0" SE="0.0" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.036705211058344" CI_START="0.013601565287485037" EFFECT_SIZE="0.33062330623306235" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9050780385582232" LOG_CI_START="-1.8664111095268476" LOG_EFFECT_SIZE="-0.4806665354843121" ORDER="1453" O_E="0.0" SE="1.6279864446777124" STUDY_ID="STD-Th_x00e9_roux-1988" TOTAL_1="122" TOTAL_2="121" VAR="2.650339864054378" WEIGHT="13.230991947401758"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.235078635290464" CI_START="0.1489467879588216" DF="0" EFFECT_SIZE="1.0380952380952382" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.859443255660605" LOG_CI_START="-0.8269688579192338" LOG_EFFECT_SIZE="0.016237198870685598" NO="3" P_CHI2="1.0" P_Z="0.9698933489617169" STUDIES="2" TAU2="0.0" TOTAL_1="142" TOTAL_2="141" WEIGHT="17.241205979632255" Z="0.03774204981106663">
<NAME>UFH + warfarin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1454" O_E="0.0" SE="0.0" STUDY_ID="STD-Cohen-1990" TOTAL_1="37" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.235078635290464" CI_START="0.1489467879588216" EFFECT_SIZE="1.0380952380952382" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.859443255660605" LOG_CI_START="-0.8269688579192338" LOG_EFFECT_SIZE="0.016237198870685598" ORDER="1455" O_E="0.0" SE="0.9906068233913923" STUDY_ID="STD-Cohen-1994" TOTAL_1="105" TOTAL_2="109" VAR="0.9813018785495851" WEIGHT="17.241205979632255"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-04-25 03:45:38 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Incidence of MI over all time periods</NAME>
<DICH_OUTCOME CHI2="3.4365151578253985" CI_END="0.6294892769396234" CI_START="0.25039309186120373" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3970135593986506" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="57" I2="0.0" I2_Q="17.63353228668652" ID="CMP-002.01" LOG_CI_END="-0.20101166349990743" LOG_CI_START="-0.6013776571227306" LOG_EFFECT_SIZE="-0.401194660311319" METHOD="MH" MODIFIED="2014-04-25 03:45:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6330148111225558" P_Q="0.29698131209505085" P_Z="8.564049592795379E-5" Q="2.4281725992684833" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1238" TOTAL_2="1188" WEIGHT="99.99999999999999" Z="3.9280413298075927">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8261306012361955" CI_END="0.5501337966457303" CI_START="0.14357184113033009" DF="1" EFFECT_SIZE="0.2810404277901066" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="36" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.2595316739997212" LOG_CI_START="-0.8429307302949842" LOG_EFFECT_SIZE="-0.5512312021473528" NO="1" P_CHI2="0.3633938630142646" P_Z="2.1240352380011494E-4" STUDIES="2" TAU2="0.0" TOTAL_1="809" TOTAL_2="793" WEIGHT="62.10626513594188" Z="3.7037883133521348">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="0.6235357571474551" CI_START="0.1536972509783812" EFFECT_SIZE="0.3095734674682043" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="33" LOG_CI_END="-0.20513863651333797" LOG_CI_START="-0.8133339002009478" LOG_EFFECT_SIZE="-0.5092362683571429" ORDER="1456" O_E="0.0" SE="0.3572569085052118" STUDY_ID="STD-FRISC-1996" TOTAL_1="741" TOTAL_2="757" VAR="0.12763249867470128" WEIGHT="54.49975443207065"/>
<DICH_DATA CI_END="1.4434728801490726" CI_START="0.004065374491499824" EFFECT_SIZE="0.07660455486542443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.1594086288040277" LOG_CI_START="-2.390899442173062" LOG_EFFECT_SIZE="-1.1157454066845172" ORDER="1457" O_E="0.0" SE="1.4980635851204949" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="2.24419450506407" WEIGHT="7.6065107038712325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005847402830536956" CI_END="1.3443643302303505" CI_START="0.22538362174651244" DF="1" EFFECT_SIZE="0.5504522701326073" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.12851698089529756" LOG_CI_START="-0.6470776466020285" LOG_EFFECT_SIZE="-0.25928033285336544" NO="2" P_CHI2="0.939046523144802" P_Z="0.19005138644571418" STUDIES="3" TAU2="0.0" TOTAL_1="287" TOTAL_2="254" WEIGHT="20.470173137840437" Z="1.3104271130189222">
<NAME>UFH</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1458" O_E="0.0" SE="0.0" STUDY_ID="STD-Doucet-2000" TOTAL_1="95" TOTAL_2="96" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.993390144029893" CI_START="0.1401570866289239" EFFECT_SIZE="0.5285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.2995923066368657" LOG_CI_START="-0.8533849385313894" LOG_EFFECT_SIZE="-0.27689631594726183" ORDER="1459" O_E="0.0" SE="0.6772645411412432" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="0.4586872586872587" WEIGHT="8.736720949319796"/>
<DICH_DATA CI_END="1.8862929767467487" CI_START="0.17028085971382692" EFFECT_SIZE="0.5667447306791569" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.27560914773465356" LOG_CI_START="-0.7688341658238387" LOG_EFFECT_SIZE="-0.24661250904459261" ORDER="1460" O_E="0.0" SE="0.6135111724620425" STUDY_ID="STD-Th_x00e9_roux-1988" TOTAL_1="122" TOTAL_2="121" VAR="0.37639595873575005" WEIGHT="11.73345218852064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.26574795509008076" CI_END="1.6200120827479056" CI_START="0.2451002932991669" DF="1" EFFECT_SIZE="0.6301312852332488" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.20951825371002147" LOG_CI_START="-0.6106561690492949" LOG_EFFECT_SIZE="-0.2005689576696367" NO="3" P_CHI2="0.6061984955095556" P_Z="0.3377623535834007" STUDIES="2" TAU2="0.0" TOTAL_1="142" TOTAL_2="141" WEIGHT="17.42356172621767" Z="0.9585959340860494">
<NAME>UFH + warfarin</NAME>
<DICH_DATA CI_END="6.867202776973055" CI_START="0.012202204678067034" EFFECT_SIZE="0.2894736842105263" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8367798715707362" LOG_CI_START="-1.9135616944879064" LOG_EFFECT_SIZE="-0.5383909114585851" ORDER="1461" O_E="0.0" SE="1.615564250313169" STUDY_ID="STD-Cohen-1990" TOTAL_1="37" TOTAL_2="32" VAR="2.610047846889952" WEIGHT="2.680345124240515"/>
<DICH_DATA CI_END="1.8767499017254061" CI_START="0.2552028251642835" EFFECT_SIZE="0.692063492063492" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2734064017969206" LOG_CI_START="-0.5931145221669121" LOG_EFFECT_SIZE="-0.15985406018499568" ORDER="1462" O_E="0.0" SE="0.5089986800841066" STUDY_ID="STD-Cohen-1994" TOTAL_1="105" TOTAL_2="109" VAR="0.25907965632736274" WEIGHT="14.743216601977156"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-04-25 03:46:04 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Incidence of recurrent angina over all time periods</NAME>
<DICH_OUTCOME CHI2="17.164962625889313" CI_END="1.0873972849158735" CI_START="0.5974370661290173" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8060095803505058" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="197" I2="65.04507390566404" I2_Q="77.3646926050792" ID="CMP-003.01" LOG_CI_END="0.03638824429239224" LOG_CI_START="-0.22370783644242936" LOG_EFFECT_SIZE="-0.09365979607501856" METHOD="MH" MODIFIED="2014-04-25 03:46:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.008695734288482804" P_Q="0.012059860395418731" P_Z="0.15808133508873853" Q="8.835753652935963" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09898897773400649" TOTALS="YES" TOTAL_1="1238" TOTAL_2="1188" WEIGHT="100.0" Z="1.4115539656559386">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.13861600879580652" CI_END="0.7420821604764498" CI_START="0.3598483840956509" DF="1" EFFECT_SIZE="0.5167562929599019" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="71" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.12954800864792465" LOG_CI_START="-0.44388044317773245" LOG_EFFECT_SIZE="-0.2867142259128286" NO="1" P_CHI2="0.7096608912756509" P_Z="3.4954432452836075E-4" STUDIES="2" TAU2="0.0" TOTAL_1="809" TOTAL_2="793" WEIGHT="27.031592409750186" Z="3.5755111144353493">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="0.7653923129735063" CI_START="0.3177834842392613" EFFECT_SIZE="0.4931825585183117" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="58" LOG_CI_END="-0.11611590381775513" LOG_CI_START="-0.4978686775821917" LOG_EFFECT_SIZE="-0.30699229069997347" ORDER="1463" O_E="0.0" SE="0.22424346901593703" STUDY_ID="STD-FRISC-1996" TOTAL_1="741" TOTAL_2="757" VAR="0.050285133396301515" WEIGHT="15.637176074945051"/>
<DICH_DATA CI_END="1.0787897047423871" CI_START="0.3013143044741842" EFFECT_SIZE="0.5701357466063348" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.03293679318045876" LOG_CI_START="-0.5209802503155543" LOG_EFFECT_SIZE="-0.2440217285675478" ORDER="1464" O_E="0.0" SE="0.3253736132831447" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="0.1058679882209294" WEIGHT="11.394416334805134"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.221801573959218" CI_END="1.242453745966373" CI_START="0.7839612565893175" DF="2" EFFECT_SIZE="0.9869324191361344" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="90" I2="9.982960519915867" ID="CMP-003.01.02" LOG_CI_END="0.09428022980337317" LOG_CI_START="-0.10570539964366724" LOG_EFFECT_SIZE="-0.005712584920147018" NO="2" P_CHI2="0.32926252093907504" P_Z="0.9108450902871387" STUDIES="3" TAU2="0.005582040599769456" TOTAL_1="287" TOTAL_2="254" WEIGHT="46.129002979085755" Z="0.11197265256581676">
<NAME>UFH</NAME>
<DICH_DATA CI_END="1.282331536166962" CI_START="0.7963334021679161" EFFECT_SIZE="1.0105263157894737" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="56" LOG_CI_END="0.10800032293106906" LOG_CI_START="-0.09890506742962776" LOG_EFFECT_SIZE="0.004547627750720661" ORDER="1465" O_E="0.0" SE="0.12153725049607368" STUDY_ID="STD-Doucet-2000" TOTAL_1="95" TOTAL_2="96" VAR="0.014771303258145364" WEIGHT="20.51880971827571"/>
<DICH_DATA CI_END="1.909514398367138" CI_START="0.7173841002767282" EFFECT_SIZE="1.170408163265306" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" LOG_CI_END="0.28092293744503766" LOG_CI_START="-0.14424825302749208" LOG_EFFECT_SIZE="0.0683373422087728" ORDER="1466" O_E="0.0" SE="0.2497476619148999" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="0.06237389463195914" WEIGHT="14.46569167337078"/>
<DICH_DATA CI_END="1.2366380530038985" CI_START="0.3360742099669175" EFFECT_SIZE="0.644672131147541" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.09224260618949696" LOG_CI_START="-0.47356481362038216" LOG_EFFECT_SIZE="-0.1906611037154426" ORDER="1467" O_E="0.0" SE="0.3323580791882216" STUDY_ID="STD-Th_x00e9_roux-1988" TOTAL_1="122" TOTAL_2="121" VAR="0.11046189280168416" WEIGHT="11.144501587439267"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.279229854085012" CI_END="1.8681150859430173" CI_START="0.4521502050647256" DF="1" EFFECT_SIZE="0.9190585504708841" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="36" I2="69.50503488633842" ID="CMP-003.01.03" LOG_CI_END="0.271403627595579" LOG_CI_START="-0.34471726785616374" LOG_EFFECT_SIZE="-0.03665682013029238" NO="3" P_CHI2="0.07016190772471365" P_Z="0.8155900984899456" STUDIES="2" TAU2="0.18500103675175583" TOTAL_1="142" TOTAL_2="141" WEIGHT="26.839404611164053" Z="0.23322061554318194">
<NAME>UFH + warfarin</NAME>
<DICH_DATA CI_END="1.9074964358676787" CI_START="0.8103049278657728" EFFECT_SIZE="1.2432432432432432" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.28046373515407613" LOG_CI_START="-0.09135151992491797" LOG_EFFECT_SIZE="0.09455610761457907" ORDER="1468" O_E="0.0" SE="0.21840612134859724" STUDY_ID="STD-Cohen-1990" TOTAL_1="37" TOTAL_2="32" VAR="0.04770123384253819" WEIGHT="15.912619758936778"/>
<DICH_DATA CI_END="1.2094467550801005" CI_START="0.3207673415788111" EFFECT_SIZE="0.6228571428571429" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="20" LOG_CI_END="0.0825867536537468" LOG_CI_START="-0.4938098551450884" LOG_EFFECT_SIZE="-0.20561155074567078" ORDER="1469" O_E="0.0" SE="0.3385782212176653" STUDY_ID="STD-Cohen-1994" TOTAL_1="105" TOTAL_2="109" VAR="0.11463521188291831" WEIGHT="10.926784852227275"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-04-25 03:46:25 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incidence of revascularization procedures over all time periods</NAME>
<DICH_OUTCOME CHI2="10.182252967371678" CI_END="1.1489821650859549" CI_START="0.7570864652376935" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9326729576792058" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="118" I2="41.073944840826655" I2_Q="67.03389238957607" ID="CMP-004.01" LOG_CI_END="0.060313287465596103" LOG_CI_START="-0.12085451781671236" LOG_EFFECT_SIZE="-0.03027061517555813" METHOD="MH" MODIFIED="2014-04-25 03:46:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11718391702739961" P_Q="0.04815089773470238" P_Z="0.5124900814274164" Q="6.066836957626132" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1297" TOTAL_2="1223" WEIGHT="99.99999999999999" Z="0.6549653283210494">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5415332867043388" CI_END="0.7841640109365298" CI_START="0.08853695813907647" DF="1" EFFECT_SIZE="0.26349097937207994" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-0.10559309344404096" LOG_CI_START="-1.0528754031399516" LOG_EFFECT_SIZE="-0.5792342482919962" NO="1" P_CHI2="0.4617980632234647" P_Z="0.016533694210291435" STUDIES="2" TAU2="0.0" TOTAL_1="809" TOTAL_2="793" WEIGHT="11.52039865550103" Z="2.396916428490853">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="1.2529007611041805" CI_START="0.09255420623078811" EFFECT_SIZE="0.34053081421502474" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.09791667305985341" LOG_CI_START="-1.033603839457689" LOG_EFFECT_SIZE="-0.46784358319891783" ORDER="1470" O_E="0.0" SE="0.6646607501696752" STUDY_ID="STD-FRISC-1996" TOTAL_1="741" TOTAL_2="757" VAR="0.4417739128161154" WEIGHT="7.2570751966226075"/>
<DICH_DATA CI_END="1.1404962147717959" CI_START="0.01535936797612901" EFFECT_SIZE="0.1323529411764706" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.05709384822165483" LOG_CI_START="-1.813626654755478" LOG_EFFECT_SIZE="-0.8782664032669114" ORDER="1471" O_E="0.0" SE="1.0988704836646042" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="1.2075163398692812" WEIGHT="4.263323458878423"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.34731966475475545" CI_END="1.2505443550716648" CI_START="0.761921833539455" DF="2" EFFECT_SIZE="0.9761234798623677" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="77" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.09709910016187967" LOG_CI_START="-0.11808958115878525" LOG_EFFECT_SIZE="-0.010495240498452775" NO="2" P_CHI2="0.8405828209126662" P_Z="0.8483816064124575" STUDIES="3" TAU2="0.0" TOTAL_1="346" TOTAL_2="289" WEIGHT="65.19329742973107" Z="0.19118378587394824">
<NAME>UFH</NAME>
<DICH_DATA CI_END="2.1709635049013882" CI_START="0.2522382337444561" EFFECT_SIZE="0.74" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.336652522785068" LOG_CI_START="-0.5981890833231156" LOG_EFFECT_SIZE="-0.13076828026902382" ORDER="1472" O_E="0.0" SE="0.5491305869685293" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="0.30154440154440154" WEIGHT="5.33208404010358"/>
<DICH_DATA CI_END="2.0345035176946844" CI_START="0.5706468027746765" EFFECT_SIZE="1.0774891774891775" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.30845844509324594" LOG_CI_START="-0.24363261166034814" LOG_EFFECT_SIZE="0.032412916716448914" ORDER="1473" O_E="0.0" SE="0.3243010196318677" STUDY_ID="STD-Holdright-1994" TOTAL_1="154" TOTAL_2="131" VAR="0.10517115133426905" WEIGHT="13.21234297937245"/>
<DICH_DATA CI_END="1.2760943346591256" CI_START="0.7440371856799763" EFFECT_SIZE="0.9744032211676733" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="57" LOG_CI_END="0.1058827805822952" LOG_CI_START="-0.12840535863147343" LOG_EFFECT_SIZE="-0.01126128902458912" ORDER="1474" O_E="0.0" SE="0.13762201271916094" STUDY_ID="STD-Th_x00e9_roux-1988" TOTAL_1="122" TOTAL_2="121" VAR="0.018939818384872895" WEIGHT="46.64887041025504"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.681385318447221" CI_END="1.7391486442564168" CI_START="0.7500052948334235" DF="1" EFFECT_SIZE="1.1420904919027575" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="28" I2="62.705844880992494" ID="CMP-004.01.03" LOG_CI_END="0.24033670254410988" LOG_CI_START="-0.12493567059653807" LOG_EFFECT_SIZE="0.057700515973785886" NO="3" P_CHI2="0.10152743562233146" P_Z="0.5357752148791093" STUDIES="2" TAU2="0.0" TOTAL_1="142" TOTAL_2="141" WEIGHT="23.286303914767885" Z="0.6192142713977047">
<NAME>UFH + warfarin</NAME>
<DICH_DATA CI_END="2.668189810351297" CI_START="0.9422424294790998" EFFECT_SIZE="1.5855855855855856" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.4262167212924935" LOG_CI_START="-0.02583734323750868" LOG_EFFECT_SIZE="0.2001896890274924" ORDER="1475" O_E="0.0" SE="0.2655387952086319" STUDY_ID="STD-Cohen-1990" TOTAL_1="37" TOTAL_2="32" VAR="0.07051085176085176" WEIGHT="10.489302218519292"/>
<DICH_DATA CI_END="1.5660408893852553" CI_START="0.3870738455786469" EFFECT_SIZE="0.7785714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.19480309731486925" LOG_CI_START="-0.412206172790098" LOG_EFFECT_SIZE="-0.10870153773761439" ORDER="1476" O_E="0.0" SE="0.35656025000400465" STUDY_ID="STD-Cohen-1994" TOTAL_1="105" TOTAL_2="109" VAR="0.1271352118829183" WEIGHT="12.797001696248591"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-04-25 03:46:55 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Incidence of multiple end points (death or myocardial infarction) over all time periods</NAME>
<DICH_OUTCOME CHI2="9.522013975844713" CI_END="0.7992956874740722" CI_START="0.4709788686218299" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6135563369250181" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="115" I2="26.486140245566915" I2_Q="70.61808094892521" ID="CMP-005.01" LOG_CI_END="-0.09729253021949619" LOG_CI_START="-0.32699857789617504" LOG_EFFECT_SIZE="-0.21214555405783558" METHOD="MH" MODIFIED="2014-04-25 03:46:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2173165447823069" P_Q="0.03325833561667557" P_Z="2.9430874044797877E-4" Q="6.806907324614794" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1602" TOTAL_2="1508" WEIGHT="100.0" Z="3.6202585838654624">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.059943182329019" CI_END="0.6137182316894422" CI_START="0.18368399378792827" DF="1" EFFECT_SIZE="0.3357532067712561" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="39" I2="5.655320334935839" ID="CMP-005.01.01" LOG_CI_END="-0.21203097496519518" LOG_CI_START="-0.735928686440206" LOG_EFFECT_SIZE="-0.47397983070270056" NO="1" P_CHI2="0.30322852630891806" P_Z="3.9048780573099366E-4" STUDIES="2" TAU2="0.0" TOTAL_1="809" TOTAL_2="793" WEIGHT="32.97091934095859" Z="3.546430447119816">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="0.6899393276456047" CI_START="0.19725414816281353" EFFECT_SIZE="0.3689083820662768" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="36" LOG_CI_END="-0.16118909886747154" LOG_CI_START="-0.7049738550119402" LOG_EFFECT_SIZE="-0.4330814769397059" ORDER="1477" O_E="0.0" SE="0.31942185753721625" STUDY_ID="STD-FRISC-1996" TOTAL_1="741" TOTAL_2="757" VAR="0.10203032307252567" WEIGHT="29.231123591940484"/>
<DICH_DATA CI_END="1.4434728801490726" CI_START="0.004065374491499824" EFFECT_SIZE="0.07660455486542443" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.1594086288040277" LOG_CI_START="-2.390899442173062" LOG_EFFECT_SIZE="-1.1157454066845172" ORDER="1478" O_E="0.0" SE="1.4980635851204949" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="2.24419450506407" WEIGHT="3.7397957490181026"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3785231635643418" CI_END="1.084426197034476" CI_START="0.5848761434553394" DF="3" EFFECT_SIZE="0.7964012882859145" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="66" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.03520000050757308" LOG_CI_START="-0.23293609273652968" LOG_EFFECT_SIZE="-0.09886804611447832" NO="2" P_CHI2="0.7105768443648524" P_Z="0.14835424276819564" STUDIES="5" TAU2="0.0" TOTAL_1="651" TOTAL_2="574" WEIGHT="58.462661099110896" Z="1.4453690830037829">
<NAME>UFH</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1479" O_E="0.0" SE="0.0" STUDY_ID="STD-Doucet-2000" TOTAL_1="95" TOTAL_2="96" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.993390144029893" CI_START="0.1401570866289239" EFFECT_SIZE="0.5285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.2995923066368657" LOG_CI_START="-0.8533849385313894" LOG_EFFECT_SIZE="-0.27689631594726183" ORDER="1480" O_E="0.0" SE="0.6772645411412432" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="0.4586872586872587" WEIGHT="4.295471752901735"/>
<DICH_DATA CI_END="1.2866517160007267" CI_START="0.6200386246017551" EFFECT_SIZE="0.8931818181818182" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" LOG_CI_END="0.10946100355615308" LOG_CI_START="-0.20758125577767453" LOG_EFFECT_SIZE="-0.04906012611076073" ORDER="1481" O_E="0.0" SE="0.18623219251718479" STUDY_ID="STD-Holdright-1994" TOTAL_1="154" TOTAL_2="131" VAR="0.03468242952975777" WEIGHT="35.47908949589714"/>
<DICH_DATA CI_END="1.6259163414027744" CI_START="0.36601024644533475" EFFECT_SIZE="0.7714285714285715" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.211098195992469" LOG_CI_START="-0.4365067563750457" LOG_EFFECT_SIZE="-0.11270428019128831" ORDER="1482" O_E="0.0" SE="0.3804063547168931" STUDY_ID="STD-RISC-1990" TOTAL_1="210" TOTAL_2="189" VAR="0.1447089947089947" WEIGHT="12.09514414632857"/>
<DICH_DATA CI_END="1.603536860729461" CI_START="0.15336001430765778" EFFECT_SIZE="0.4959016393442623" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.20507894756811293" LOG_CI_START="-0.8142878596126716" LOG_EFFECT_SIZE="-0.30460445602227937" ORDER="1483" O_E="0.0" SE="0.5987811084850684" STUDY_ID="STD-Th_x00e9_roux-1988" TOTAL_1="122" TOTAL_2="121" VAR="0.35853881587860725" WEIGHT="6.592955703983452"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0736790101012533" CI_END="1.2751486833502432" CI_START="0.1483475261631215" DF="1" EFFECT_SIZE="0.43493120451994494" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.10556082680434341" LOG_CI_START="-0.8287196915625995" LOG_EFFECT_SIZE="-0.36157943237912804" NO="3" P_CHI2="0.7860535873017405" P_Z="0.12924998865609025" STUDIES="2" TAU2="0.0" TOTAL_1="142" TOTAL_2="141" WEIGHT="8.566419559930516" Z="1.5170661296721772">
<NAME>UFH + warfarin</NAME>
<DICH_DATA CI_END="6.867202776973055" CI_START="0.012202204678067034" EFFECT_SIZE="0.2894736842105263" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8367798715707362" LOG_CI_START="-1.9135616944879064" LOG_EFFECT_SIZE="-0.5383909114585851" ORDER="1484" O_E="0.0" SE="1.615564250313169" STUDY_ID="STD-Cohen-1990" TOTAL_1="37" TOTAL_2="32" VAR="2.610047846889952" WEIGHT="1.3178109769088373"/>
<DICH_DATA CI_END="1.4525942861358376" CI_START="0.14654298377841954" EFFECT_SIZE="0.4613756613756614" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1621443315061168" LOG_CI_START="-0.8340349699874706" LOG_EFFECT_SIZE="-0.3359453192406769" ORDER="1485" O_E="0.0" SE="0.5851606528644044" STUDY_ID="STD-Cohen-1994" TOTAL_1="105" TOTAL_2="109" VAR="0.34241298966069605" WEIGHT="7.248608583021679"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-04-25 03:47:18 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Incidence of major bleeds over all time periods</NAME>
<DICH_OUTCOME CHI2="1.3916151856625059" CI_END="4.598677219694637" CI_START="0.9094654649114527" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0450765549453864" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.6626329275942517" LOG_CI_START="-0.041213787730955284" LOG_EFFECT_SIZE="0.3107095699316482" METHOD="MH" MODIFIED="2014-04-25 03:47:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9252282945130929" P_Q="0.6355542382230156" P_Z="0.08355305621366563" Q="0.906515782369278" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1607" TOTAL_2="1511" WEIGHT="100.0" Z="1.7304323610761911">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.3933682772988565" CI_START="0.43298412274588055" DF="0" EFFECT_SIZE="1.5281501340482573" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.7318600763864254" LOG_CI_START="-0.36352802865881784" LOG_EFFECT_SIZE="0.18416602386380376" NO="1" P_CHI2="1.0" P_Z="0.5098624832425942" STUDIES="2" TAU2="0.0" TOTAL_1="814" TOTAL_2="796" WEIGHT="45.59533486522366" Z="0.6590518416010931">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="5.3933682772988565" CI_START="0.43298412274588055" EFFECT_SIZE="1.5281501340482573" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7318600763864254" LOG_CI_START="-0.36352802865881784" LOG_EFFECT_SIZE="0.18416602386380376" ORDER="1486" O_E="0.0" SE="0.6434363951621449" STUDY_ID="STD-FRISC-1996" TOTAL_1="746" TOTAL_2="760" VAR="0.4140103946192559" WEIGHT="45.59533486522366"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1487" O_E="0.0" SE="0.0" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4609321040015331" CI_END="6.255889946567288" CI_START="0.5917787492143798" DF="3" EFFECT_SIZE="1.9240849065990833" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.7962891000231873" LOG_CI_START="-0.22784063441809876" LOG_EFFECT_SIZE="0.2842242328025443" NO="2" P_CHI2="0.927386725146337" P_Z="0.2766445404582567" STUDIES="5" TAU2="0.0" TOTAL_1="651" TOTAL_2="574" WEIGHT="48.758303616753636" Z="1.0878880694357023">
<NAME>UFH</NAME>
<DICH_DATA CI_END="73.48789281353443" CI_START="0.1250338825990631" EFFECT_SIZE="3.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8662157946299598" LOG_CI_START="-0.9029722827372821" LOG_EFFECT_SIZE="0.4816217559463389" ORDER="1488" O_E="0.0" SE="1.626634784347576" STUDY_ID="STD-Doucet-2000" TOTAL_1="95" TOTAL_2="96" VAR="2.6459407216494846" WEIGHT="5.723088886387656"/>
<DICH_DATA CI_END="54.328156840563885" CI_START="0.13181521223546824" EFFECT_SIZE="2.676056338028169" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.735024971230098" LOG_CI_START="-0.8800344667625907" LOG_EFFECT_SIZE="0.4274952522337537" ORDER="1489" O_E="0.0" SE="1.5360988586298938" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="2.3595997034840623" WEIGHT="7.494599293785365"/>
<DICH_DATA CI_END="13.467045461073356" CI_START="0.053731482517954544" EFFECT_SIZE="0.8506493506493507" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1292723261835396" LOG_CI_START="-1.269771176544937" LOG_EFFECT_SIZE="-0.07024942518069881" ORDER="1490" O_E="0.0" SE="1.4092100289595706" STUDY_ID="STD-Holdright-1994" TOTAL_1="154" TOTAL_2="131" VAR="1.985872905720234" WEIGHT="12.434330985468856"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1491" O_E="0.0" SE="0.0" STUDY_ID="STD-RISC-1990" TOTAL_1="210" TOTAL_2="189" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.628772337488897" CI_START="0.37019279833392504" EFFECT_SIZE="1.9836065573770492" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0264831048013392" LOG_CI_START="-0.4315720341899731" LOG_EFFECT_SIZE="0.297455535305683" ORDER="1492" O_E="0.0" SE="0.856468806132837" STUDY_ID="STD-Th_x00e9_roux-1988" TOTAL_1="122" TOTAL_2="121" VAR="0.7335388158786073" WEIGHT="23.106284451111758"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="138.94890020786343" CI_START="0.37976471098011627" DF="0" EFFECT_SIZE="7.264150943396227" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="2.1428551136499405" LOG_CI_START="-0.4204853938345174" LOG_EFFECT_SIZE="0.8611848599077117" NO="3" P_CHI2="1.0" P_Z="0.18785651781349597" STUDIES="2" TAU2="0.0" TOTAL_1="142" TOTAL_2="141" WEIGHT="5.646361518022699" Z="1.3169466206475269">
<NAME>UFH + warfarin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1493" O_E="0.0" SE="0.0" STUDY_ID="STD-Cohen-1990" TOTAL_1="37" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="138.94890020786343" CI_START="0.37976471098011644" EFFECT_SIZE="7.264150943396227" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1428551136499405" LOG_CI_START="-0.42048539383451716" LOG_EFFECT_SIZE="0.8611848599077117" ORDER="1494" O_E="0.0" SE="1.5057189028365239" STUDY_ID="STD-Cohen-1994" TOTAL_1="105" TOTAL_2="109" VAR="2.2671894143592253" WEIGHT="5.646361518022699"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-04-25 03:47:41 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Incidence of minor bleeds over all time periods</NAME>
<DICH_OUTCOME CHI2="9.05455655794484" CI_END="37.49114828971807" CI_START="1.2345752599011526" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="6.803355359215872" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="5" I2="66.86751050919577" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="1.5739287423220842" LOG_CI_START="0.09151756973455195" LOG_EFFECT_SIZE="0.832723156028318" METHOD="MH" MODIFIED="2014-04-25 03:47:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.028574287193479653" P_Q="0.4851676660800265" P_Z="0.027667910871432708" Q="1.4465218106397193" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.8860561250749006" TOTALS="YES" TOTAL_1="989" TOTAL_2="942" WEIGHT="100.0" Z="2.201963159869075">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.903003885619317" CI_END="177.0821621952293" CI_START="0.5605741363298549" DF="1" EFFECT_SIZE="9.96331672346182" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="2" I2="65.55292244169135" ID="CMP-007.01.01" LOG_CI_END="2.2481748161288344" LOG_CI_START="-0.251366943515337" LOG_EFFECT_SIZE="0.9984039363067487" NO="1" P_CHI2="0.08841478982551843" P_Z="0.11740584365466868" STUDIES="2" TAU2="2.986654278101543" TOTAL_1="814" TOTAL_2="796" WEIGHT="48.404642480827064" Z="1.5657556027092103">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="126.61268947696243" CI_START="7.625564067763102" EFFECT_SIZE="31.072386058981234" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="2" LOG_CI_END="2.102477234067208" LOG_CI_START="0.8822719742426087" LOG_EFFECT_SIZE="1.4923746041549084" ORDER="1495" O_E="0.0" SE="0.7167546097344196" STUDY_ID="STD-FRISC-1996" TOTAL_1="746" TOTAL_2="760" VAR="0.5137371705755401" WEIGHT="31.59648178328362"/>
<DICH_DATA CI_END="38.51381973968138" CI_START="0.06719410639648646" EFFECT_SIZE="1.608695652173913" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5856165933981161" LOG_CI_START="-1.1726688172993118" LOG_EFFECT_SIZE="0.20647388804940212" ORDER="1496" O_E="0.0" SE="1.6202305039766567" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="2.625146886016451" WEIGHT="16.808160697543446"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="186.60225225845807" CI_START="0.676974334445307" DF="0" EFFECT_SIZE="11.239436619718308" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="2.2709168813049994" LOG_CI_START="-0.16942779604169125" LOG_EFFECT_SIZE="1.0507445426316542" NO="2" P_CHI2="1.0" P_Z="0.09144733194275037" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="37" WEIGHT="19.240564860626282" Z="1.6878119551121749">
<NAME>UFH</NAME>
<DICH_DATA CI_END="186.60225225845807" CI_START="0.676974334445307" EFFECT_SIZE="11.23943661971831" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.2709168813049994" LOG_CI_START="-0.16942779604169125" LOG_EFFECT_SIZE="1.0507445426316542" ORDER="1497" O_E="0.0" SE="1.433470543374421" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="2.0548377987221578" WEIGHT="19.240564860626282"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.119084201340263" CI_START="0.6433936088631405" DF="0" EFFECT_SIZE="2.422222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="0.9599512257982692" LOG_CI_START="-0.19152325746770923" LOG_EFFECT_SIZE="0.3842139841652799" NO="3" P_CHI2="1.0" P_Z="0.19088435013118216" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="109" WEIGHT="32.35479265854666" Z="1.3079674491521422">
<NAME>UFH + warfarin</NAME>
<DICH_DATA CI_END="9.119084201340263" CI_START="0.6433936088631405" EFFECT_SIZE="2.422222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9599512257982692" LOG_CI_START="-0.19152325746770923" LOG_EFFECT_SIZE="0.3842139841652799" ORDER="1498" O_E="0.0" SE="0.6763818113610545" STUDY_ID="STD-Cohen-1994" TOTAL_1="105" TOTAL_2="109" VAR="0.4574923547400611" WEIGHT="32.35479265854666"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-04-25 03:47:59 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Incidence of thrombocytopenia over all time periods</NAME>
<DICH_OUTCOME CHI2="2.0565984567372028E-32" CI_END="4.236828019723687" CI_START="0.009798221786510908" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2037483266398929" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="100.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.6270408355844498" LOG_CI_START="-2.008852734346139" LOG_EFFECT_SIZE="-0.6909059493808448" METHOD="MH" MODIFIED="2014-04-25 03:47:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.30419922119071763" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="884" TOTAL_2="833" WEIGHT="100.0" Z="1.0274699957074278">
<NAME>Heparin vs placebo or untreated control</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0565984567372028E-32" CI_END="4.236828019723687" CI_START="0.009798221786510908" DF="0" EFFECT_SIZE="0.2037483266398929" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="100.0" ID="CMP-008.01.01" LOG_CI_END="0.6270408355844498" LOG_CI_START="-2.008852734346139" LOG_EFFECT_SIZE="-0.6909059493808448" NO="1" P_CHI2="0.0" P_Z="0.30419922119071763" STUDIES="2" TAU2="0.0" TOTAL_1="814" TOTAL_2="796" WEIGHT="100.0" Z="1.0274699957074278">
<NAME>LMWH</NAME>
<DICH_DATA CI_END="4.236828019723687" CI_START="0.009798221786510908" EFFECT_SIZE="0.2037483266398929" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6270408355844498" LOG_CI_START="-2.008852734346139" LOG_EFFECT_SIZE="-0.6909059493808448" ORDER="1499" O_E="0.0" SE="1.5483369308608328" STUDY_ID="STD-FRISC-1996" TOTAL_1="746" TOTAL_2="760" VAR="2.397347251467543" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1500" O_E="0.0" SE="0.0" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="68" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>UFH</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1501" O_E="0.0" SE="0.0" STUDY_ID="STD-Gurfinkel-1995" TOTAL_1="70" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>UFH + warfarin</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-06-19 20:50:53 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-06-19 20:50:53 +0100" MODIFIED_BY="Heather Maxwell" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUQAAAJxCAIAAAC111wSAABWM0lEQVR42u19CVQVV9Y1iiOioEwq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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-06-19 20:50:53 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAm8AAAEACAMAAADSomGoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-06-18 14:52:47 +0100" MODIFIED_BY="Heather Maxwell" NO="3" REF_ID="CMP-005.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 5 Incidence of multiple end points (death or myocardial infarction) over all time periods, outcome: 5.1 Heparin vs placebo or untreated control.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-04-01 16:44:18 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2014-04-01 16:44:18 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-07-27 10:53:59 +0100" MODIFIED_BY="Joey Kwong">From David Cundiff</TITLE>
<DATE_SUBMITTED>
<DATE DAY="28" MONTH="8" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2014-04-01 16:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>I thank Drs. Magee, Moher, and Rowe for completing the review.</P>
<P>The phenomenon of reactivation of unstable angina after the discontinuation of heparin has been described by Theroux.<SUP>1</SUP> Even when aspirin is added to heparin in patients with unstable angina, the benefit of the heparin in preventing MIs ceases after the infusion.<SUP>2-5</SUP> Rebound hypercoagulability with reactivation of angina and/or MI has not been ruled out with LMWH. If overall mortality is improved with heparins, despite the rebound hypercoagulability and reactivation of unstable angina problem and the serious bleeding risk, then using one of these drugs would be justified. However, if heparin use merely delays MIs until the withdrawal period without reducing mortality, then the additional bleeding risk would move the risk-benefit analysis toward an assessment of net harm.</P>
<P>Over 60% of the subjects in the 8 RCTs in this meta-analysis came from the FRISC study using dalteparin published in 1995. This RCT contains 94% of the subjects receiving LMWHs. The conclusions of this review depend entirely on this RCT. The ACC/AHA 2007 Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction states, &#8220;Dalteparin was evaluated for management of patients with UA/NSTEMI in an era before the widespread use of important therapies such as stents, clopidogrel, and GP IIb/IIIa inhibitors. Its relative efficacy and safety in the contemporary management era is not well established.&#8221;<SUP>6</SUP>
</P>
<P>In the FRISC trial, dalteparin 120 IU / kg q12 hours was given the first 6 days and then 7500 IU qd for the next 35-40 days. The incidence of death or MI in the first 6 days strongly favoured dalteparin over placebo (13/743 versus 36/759, p &lt; 0.001). However, the event rate of deaths or MIs from days 7-14 after the reduction in dalteparin dose non significantly favoured placebo (13/724 versus 7/721, p = 0.19), suggesting a rebound effect. At 42 days into the trial just before the maintenance dose of dalteparin was stopped, the combined endpoint of deaths and MIs only marginally favoured anticoagulation (p = 0.07). At 6 months, the only data point after the dalteparin was discontinued, there was no significant difference in the combined death and MI endpoint (placebo: 116/749 versus dalteparin: 102/726, p = 0.41). Deaths were not significantly different (placebo: 41/749 versus dalteparin: 39/726). Two questions arise: (1) Are any short term benefits are off-set by later excess mortality? and (2) Are the major and fatal bleeding risks of heparins more than off-set by a significant reduction in mortality? The answer to both questions is &#8220;no.&#8221; However, the short term benefit of deferring MIs until immediately after discontinuation of anticoagulation cannot justify the risk of heparins. According to a meta-analysis by Landefeld and colleagues, &#8220;The average daily frequencies of fatal, major, and major or minor bleeding during heparin therapy were 0.05%, 0.8%, and 2.0%, respectively; these frequencies are approximately twice those expected without heparin therapy.&#8221;<SUP>7</SUP> For each 1 million people with ACS treated with 10-day courses of heparins, the anticoagulant would cause 2500 bleeding deaths and 40,000 major bleeds.</P>
<P>In conclusion, since injectable anticoagulants do not reduce either early or late mortality in acute coronary syndrome and merely delay heart attacks until immediately after the infusion, the risk of major, permanently disabling, and fatal bleeding (much greater now than when these studies were done) is not justified. </P>
<SUBSECTION>
<HEADING LEVEL="4">References</HEADING>
<OL>
<LI>Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. <I>N Engl J Med. </I>July 16, 1992;327(3):141-145.</LI>
<LI>Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. <I>New England Journal of Medicine. </I>1988;319:1105-1111.</LI>
<LI>Cohen M, Adams P, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q- wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. <I>Circulation. </I>January 1, 1994;89(1):81-88.</LI>
<LI>Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. <I>Lancet. </I>1990;336:830-837.</LI>
<LI>Theroux P WD, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. <I>Circulation. </I>November 1, 1993;88(5):2045-2048.</LI>
<LI>Anderson JL AC, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B;. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. 10.1016/j.jacc.2007.02.013. <I>J Am Coll Cardiol. </I>August 14, 2007;50(7):e1-157.</LI>
<LI>Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. <I>American Journal of Medicine. </I>1993;95(3):315-328.</LI>
</OL>
</SUBSECTION>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2010-07-27 10:58:30 +0100" MODIFIED_BY="Joey Kwong">
<P>Our research team would like to thank Dr. Cundiff for his comments on our review. </P>
<P>Dr. Cundiff contends that the short term benefits of heparin are not offset by later mortality and morbidity; however, we disagree.  While studies included in this review reported outcome data restricted to the acute phase of interventions, nearly 17% of enrolled subjects had outcomes reported at 3 months.  Dr. Cundiff is correct in pointing out that the majority of subjects in this systematic review came from the FRISC study; however, the number is in fact 48% (1498/3110) and not over 60% as he has suggested.  While this systematic review was underpowered to detect a treatment difference in rare outcomes such as mortality between heparins and placebo, it did demonstrate that heparins reduced the incidence of myocardial infarction with a NNT of 33.  Although there was a trend towards more major bleeds in the heparin group, this was non-significant with an actual risk difference of 0.6% between subjects treated with heparins and placebo over the course of the treatment in included studies.</P>
<P>We stand by our assertion that heparins appear to be a safe and effective treatment for acute coronary syndromes.  Head-to-head comparisons of low molecular weight heparins with unfractionated heparin suggest that LMWHs have a decreased risk of myocardial infarction, the need for urgent revascularization and thrombocytopenia.<SUP>1</SUP>  Finally, this is concordant with the most recent ACC/AHA Guidelines.<SUP>2</SUP>
</P>
<SUBSECTION>
<HEADING LEVEL="4">References</HEADING>
<P>1. Magee K, Sevcik WW, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. <I>Cochrane Database of Systematic Reviews</I> 2003, Issue 1. Art. No.: CD002132. DOI: 10.1002/14651858.CD002132.</P>
<P>2. Anderson JL AC, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B;. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. 10.1016/j.jacc.2007.02.013. <I>J Am Coll Cardiol. </I>August 14, 2007;50(7):e1-157.</P>
</SUBSECTION>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2014-02-03 19:02:42 +0000" MODIFIED_BY="Joey Kwong">
<P>Carlos A. Andrade-Castellanos</P>
<P>Luis E. Colunga-Lozano</P>
<P>Netzahualpilli Delgado-Figueroa</P>
<P>Kirk Magee</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2014-02-03 19:02:57 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-02-03 19:02:57 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-01-29 17:54:19 +0000" MODIFIED_BY="[Empty name]">Search strategies 2014</TITLE>
<APPENDIX_BODY MODIFIED="2014-02-03 19:02:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL on The Cochrane Library (issue 12, 2013)</B>
</P>
<P>#1 MeSH descriptor: [Heparin] explode all trees</P>
<P>#2 heparin in All Text</P>
<P>#3 lmwh in All Text</P>
<P>#4 nadroparin in All Text</P>
<P>#5 fraxiparin in All Text</P>
<P>#6 enoxaparin in All Text</P>
<P>#7 clexane in All Text</P>
<P>#8 lovenox in All Text</P>
<P>#9 dalteparin in All Text</P>
<P>#10 fragmin in All Text</P>
<P>#11 ardeparin in All Text</P>
<P>#12 normiflo in All Text</P>
<P>#13 tinzapain in All Text</P>
<P>#14 logiparin in All Text</P>
<P>#15 innohep in All Text</P>
<P>#16 certoparin in All Text</P>
<P>#17 sandoparin in All</P>
<P>#18 reviparin in All Text</P>
<P>#19 clivarin in All Text</P>
<P>#20 UFH</P>
<P>#21 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20</P>
<P>#22 MeSH descriptor: [Acute Coronary Syndrome] this term only</P>
<P>#23 MeSH descriptor: [Angina, Unstable] explode all trees</P>
<P>#24 MeSH descriptor: [Myocardial Infarction] this term only</P>
<P>#25 non-Q-wave in All Text</P>
<P>#26 non-st-segment in All Text</P>
<P>#27 "without st segment" in All Text</P>
<P>#28 NSTEMI in All Text</P>
<P>#29 unstable next angina in All Text</P>
<P>#30 (coronary in All Text near/3 syndrome* in All Text)</P>
<P>#31 (unstable in All Text near/3 coronary in All Text)</P>
<P>#32 #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31</P>
<P>#33 #21 and #32 from 2001 to 2014</P>
<P>
<B>MEDLINE OVID </B>
</P>
<P>1. exp Heparin/</P>
<P>2. heparin.tw.</P>
<P>3. lmwh.tw.</P>
<P>4. nadroparin.tw.</P>
<P>5. fraxiparin.tw.</P>
<P>6. enoxaparin.tw.</P>
<P>7. clexane.tw.</P>
<P>8. lovenox.tw.</P>
<P>9. dalteparin.tw.</P>
<P>10. fragmin.tw.</P>
<P>11. ardeparin.tw.</P>
<P>12. normiflo.tw.</P>
<P>13. tinzapain.tw.</P>
<P>14. logiparin.tw.</P>
<P>15. innohep.tw.</P>
<P>16. certoparin.tw.</P>
<P>17. sandoparin.tw.</P>
<P>18. reviparin.tw.</P>
<P>19. clivarin.tw.</P>
<P>20. UFH.tw.</P>
<P>21. or/1-20</P>
<P>22. Acute Coronary Syndrome/</P>
<P>23. exp Angina, Unstable/</P>
<P>24. Myocardial Infarction/</P>
<P>25. non st segment.tw.</P>
<P>26. without st segment.tw.</P>
<P>27. non-Q-wave.tw.</P>
<P>28. NSTEMI.tw.</P>
<P>29. unstable angina.tw.</P>
<P>30. coronary syndrome$.tw.</P>
<P>31. unstable coronary.tw.</P>
<P>32. or/22-31</P>
<P>33. 21 and 32</P>
<P>34. randomized controlled trial.pt.</P>
<P>35. controlled clinical trial.pt.</P>
<P>36. randomized.ab.</P>
<P>37. placebo.ab.</P>
<P>38. clinical trials as topic.sh.</P>
<P>39. randomly.ab.</P>
<P>40. trial.ti.</P>
<P>41. 34 or 35 or 36 or 37 or 38 or 39 or 40</P>
<P>42. exp animals/ not humans.sh.</P>
<P>43. 41 not 42</P>
<P>44. 33 and 43</P>
<P>45. (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014*).ed.</P>
<P>46. 44 and 45</P>
<P>
<B>EMBASE OVID</B>
</P>
<P>1. exp Heparin/</P>
<P>2. heparin.tw.</P>
<P>3. lmwh.tw.</P>
<P>4. nadroparin.tw.</P>
<P>5. fraxiparin.tw.</P>
<P>6. enoxaparin.tw.</P>
<P>7. clexane.tw.</P>
<P>8. lovenox.tw.</P>
<P>9. dalteparin.tw.</P>
<P>10. fragmin.tw.</P>
<P>11. ardeparin.tw.</P>
<P>12. normiflo.tw.</P>
<P>13. tinzapain.tw.</P>
<P>14. logiparin.tw.</P>
<P>15. innohep.tw.</P>
<P>16. certoparin.tw.</P>
<P>17. sandoparin.tw.</P>
<P>18. reviparin.tw.</P>
<P>19. clivarin.tw.</P>
<P>20. UFH.tw.</P>
<P>21. or/1-20</P>
<P>22. Acute Coronary Syndrome/</P>
<P>23. exp Angina, Unstable/</P>
<P>24. Myocardial Infarction/</P>
<P>25. non st segment.tw.</P>
<P>26. without st segment.tw.</P>
<P>27. non-Q-wave.tw.</P>
<P>28. NSTEMI.tw.</P>
<P>29. unstable angina.tw.</P>
<P>30. coronary syndrome$.tw.</P>
<P>31. unstable coronary.tw.</P>
<P>32. or/22-31</P>
<P>33. 21 and 32</P>
<P>34. random$.tw.</P>
<P>35. factorial$.tw.</P>
<P>36. crossover$.tw.</P>
<P>37. cross over$.tw.</P>
<P>38. cross-over$.tw.</P>
<P>39. placebo$.tw.</P>
<P>40. (doubl$ adj blind$).tw.</P>
<P>41. (singl$ adj blind$).tw.</P>
<P>42. assign$.tw.</P>
<P>43. allocat$.tw.</P>
<P>44. volunteer$.tw.</P>
<P>45. crossover procedure/</P>
<P>46. double blind procedure/</P>
<P>47. randomized controlled trial/</P>
<P>48. single blind procedure/</P>
<P>49. 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48</P>
<P>50. (animal/ or nonhuman/) not human/</P>
<P>51. 49 not 50</P>
<P>52. 33 and 51</P>
<P>53. (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014*).em.</P>
<P>54. (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014*).dd.</P>
<P>55. 53 or 54</P>
<P>56. 52 and 55</P>
<P>57. limit 56 to embase</P>
<P>
<B>CINAHL</B>
</P>
<P>S39 S38 AND S37</P>
<P>S38 EM 2002-2014</P>
<P>S37 S18 AND S36</P>
<P>S36 S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35</P>
<P>S35 TX cross-over*</P>
<P>S34 TX crossover*</P>
<P>S33 TX volunteer*</P>
<P>S32 (MH "Crossover Design")</P>
<P>S31 TX allocat*</P>
<P>S30 TX control*</P>
<P>S29 TX assign*</P>
<P>S28 TX placebo*</P>
<P>S27 (MH "Placebos")</P>
<P>S26 TX random*</P>
<P>S25 TX (doubl* N1 mask*)</P>
<P>S24 TX (singl* N1 mask*)</P>
<P>S23 TX (doubl* N1 blind*)</P>
<P>S22 TX (singl* N1 blind*)</P>
<P>S21 TX (clinic* N1 trial?)</P>
<P>S20 PT clinical trial</P>
<P>S19 (MH "Clinical Trials+")</P>
<P>S18 S6 AND S17</P>
<P>S17 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16</P>
<P>S16 "unstable coronary"</P>
<P>S15 "coronary syndrome*"</P>
<P>S14 "unstable angina"</P>
<P>S13 NSTEMI</P>
<P>S12 "non-Q-wave" or "non Q wave"</P>
<P>S11 "without st segment"</P>
<P>S10 "non st segment"</P>
<P>S9 (MH "Myocardial Infarction+")</P>
<P>S8 (MH "Angina, Unstable")</P>
<P>S7 (MH "Acute Coronary Syndrome")</P>
<P>S6 S1 OR S2 OR S3 OR S4 OR S5</P>
<P>S5 sandoparin or reviparin or clivarin or UFH</P>
<P>S4 normiflo or tinzapain or logiparin or innohep or certoparin</P>
<P>S3 clexane or lovenox or dalteparin or fragmin or ardeparin</P>
<P>S2 heparin or lmwh or nadroparin or fraxiparin or enoxaparin</P>
<P>S1 (MH "Heparin+")</P>
<P>
<B>LILACS</B>
</P>
<P>heparin$ [Words] and (coronary$ OR angina$ OR myocard$) [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>